alendronate has been researched along with Bone Loss, Osteoclastic in 371 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin." | 9.19 | Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014) |
| "The purpose of this study was to investigate the effect of alendronate on metacarpal and lumbar bone mineral density (BMD), bone resorption, and chronic back pain in postmenopausal women with osteoporosis." | 9.11 | Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2004) |
| "The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids." | 9.11 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. ( Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F, 2005) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 9.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "Alendronate treatment for 12 months in pediatric patients with rheumatic diseases and secondary low bone mass was reported to result in a substantial increase in bone mineral density (BMD)." | 9.10 | Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. ( Bardare, M; Bianchi, ML; Chiesa, S; Cimaz, R; Corona, F; Dubini, A; Falcini, F; Gattorno, M; Lenhardt, A; Lepore, L; Martini, G; Masi, L; Sormani, MP; Zulian, F, 2002) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 9.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "The purpose of the present study was to compare the effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living (ADL) in elderly women with vertebral fractures." | 9.10 | Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003) |
| "Alendronate (Aln) has been the first-line drug for osteogenesis imperfecta (OI), while the comparable efficacy of Aln and strontium ranelate (SrR) remains unclear." | 8.02 | Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta. ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "By using an experimental model of dexamethasone-induced osteoporosis we investigated the effects of different therapeutic schemes combining sodium alendronate (SA) and simvastatin on bone mineral and protein composition, microstructural and mechanical remodeling." | 7.85 | Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. ( Gonçalves, RV; Maldonado, IRSC; Novaes, RD; Oliveira, MGA; Oliveira, TT; Pinto, AS; Sequetto, PL, 2017) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 7.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| "Sodium alendronate preserves alveolar bone resorption and has anti-inflammatory and antibacterial activities in experimental periodontitis." | 7.73 | Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. ( Brito, GA; Carvalho, CB; Chaves, HV; Menezes, AM; Ribeiro, RA; Rocha, FA, 2005) |
| "To evaluate the anti-osteoporosis effect of alendronate on bone in rat model." | 7.71 | [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model]. ( Wang, X; Yang, Z; Yu, S, 2001) |
| "Galactosylhydroxylysine appears to be a sensitive index of bone resorption, useful in the clinical assessment of bone involvement and in the management of patients with mild primary hyperparathyroidism." | 7.69 | Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. ( Bertoldo, F; Bettica, P; Braga, V; LoCascio, V; Moro, L; Pasini, AF; Stefani, L, 1994) |
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 7.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| " To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0." | 6.78 | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. ( Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K, 2013) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 6.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women." | 6.71 | Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | 6.69 | Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| " Subgroup analysis revealed that among the patients in the combination therapy group, greater increases in the spine BMD were observed when the PTH was administered with a dosage of 20 μg (WMD = 2." | 6.52 | Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. ( Chen, J; Fan, J; Gu, M; Li, B; Wang, C; Zhang, G, 2015) |
| "Overactive bone resorption and limited bone formation lead to unstable combination between bone tissue and scaffolds." | 6.44 | An osteoporosis bone defect regeneration strategy via three-dimension short fibers loaded with alendronate modified hydroxyapatite. ( Cheng, Z; Dai, Z; Jia, W; Jiang, X; Jiao, K; Liu, G; Liu, L; Liu, Y; Luo, Y; Sun, M; Wang, H; Wang, S; Yang, T; Yang, Y, 2024) |
| "Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling." | 5.40 | Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. ( de Blois, E; de Jong, M; Groen, HC; Koelewijn, SJ; Müller, C; Siebelt, M; Verhaar, JA; Waarsing, JH; Weinans, H, 2014) |
| "Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease." | 5.36 | Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010) |
| "Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption." | 5.31 | Effects of alendronate on particle-induced osteolysis in a rat model. ( Allen, MJ; Bostrom, MP; Millett, PJ, 2002) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| " The current treatment for preventing and treating osteoporotic fractures is the use of antiresorptive drugs such as bisphosphonates (BPs) and denosumab, but unfortunately, their long-term use, especially with alendronate and ibandronate, has been associated with increased risk of atypical femoral fractures (AFFs); femoral diaphyseal fractures distal to the lesser trochanter but proximal to the supracondylar flare." | 5.22 | Effects of bisphosphonates on appendicular fracture repair in rodents. ( Hadjiargyrou, M, 2022) |
| "A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin." | 5.19 | Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. ( Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M, 2014) |
| "The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia." | 5.14 | Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. ( Stepan, JJ; Zikan, V, 2009) |
| " The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD." | 5.12 | Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K, 2006) |
| "The purpose of this study was to investigate the effect of alendronate on metacarpal and lumbar bone mineral density (BMD), bone resorption, and chronic back pain in postmenopausal women with osteoporosis." | 5.11 | Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2004) |
| "The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids." | 5.11 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. ( Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F, 2005) |
| "The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis." | 5.11 | Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004) |
| "Alendronate treatment for 12 months in pediatric patients with rheumatic diseases and secondary low bone mass was reported to result in a substantial increase in bone mineral density (BMD)." | 5.10 | Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. ( Bardare, M; Bianchi, ML; Chiesa, S; Cimaz, R; Corona, F; Dubini, A; Falcini, F; Gattorno, M; Lenhardt, A; Lepore, L; Martini, G; Masi, L; Sormani, MP; Zulian, F, 2002) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 5.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "The purpose of the present study was to compare the effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living (ADL) in elderly women with vertebral fractures." | 5.10 | Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003) |
| " We conducted a 1-year, single-center, prospective, randomized, double-blind study to determine whether bone loss would occur in the distal radius after a Colles' fracture and whether this loss could be prevented using an antiresorptive drug (alendronate)." | 5.09 | The effect of alendronate on bone mass after distal forearm fracture. ( Haarman, H; Lips, P; Patka, P; van der Poest Clement, E; Vandormael, K, 2000) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "Alendronate (Aln) has been the first-line drug for osteogenesis imperfecta (OI), while the comparable efficacy of Aln and strontium ranelate (SrR) remains unclear." | 4.02 | Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta. ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "By using an experimental model of dexamethasone-induced osteoporosis we investigated the effects of different therapeutic schemes combining sodium alendronate (SA) and simvastatin on bone mineral and protein composition, microstructural and mechanical remodeling." | 3.85 | Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. ( Gonçalves, RV; Maldonado, IRSC; Novaes, RD; Oliveira, MGA; Oliveira, TT; Pinto, AS; Sequetto, PL, 2017) |
| "We conducted a retrospective study in our facility for comparing the pharmacological effects of teriparatide and alendronate on 32 NOFH patients diagnosed with osteoporosis." | 3.85 | Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate. ( Arai, R; Asano, T; Inoue, M; Irie, T; Iwasaki, N; Kondo, E; Konno, T; Onodera, T; Takahashi, D; Terkawi, MA, 2017) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 3.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| "Alendronate reduces pain, improves function and retards AVN progression." | 3.73 | Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. ( Agarwala, S; Jain, D; Joshi, VR; Sule, A, 2005) |
| "Alendronate, an inhibitor of bone resorption, is widely used in osteoporosis treatment." | 3.73 | Severely suppressed bone turnover: a potential complication of alendronate therapy. ( Gottschalk, FA; Maalouf, N; Odvina, CV; Pak, CY; Rao, DS; Zerwekh, JE, 2005) |
| " In this study, we investigated the possible direct effect of three N-containing BPs (alendronate, pamidronate, and zoledronate) on the specific activity of bone ALP obtained from an extract of UMR106 rat osteosarcoma cells." | 3.73 | Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. ( Cortizo, AM; McCarthy, AD; Vaisman, DN, 2005) |
| "Sodium alendronate preserves alveolar bone resorption and has anti-inflammatory and antibacterial activities in experimental periodontitis." | 3.73 | Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. ( Brito, GA; Carvalho, CB; Chaves, HV; Menezes, AM; Ribeiro, RA; Rocha, FA, 2005) |
| "To evaluate the anti-osteoporosis effect of alendronate on bone in rat model." | 3.71 | [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model]. ( Wang, X; Yang, Z; Yu, S, 2001) |
| "We have evaluated three commercial assays for collagen cross-links, two urine assays and a recently developed serum assay, as markers of bone turnover in 30 postmenopausal women with osteoporosis during their first year of treatment with the anti-resorptive drug alendronate." | 3.70 | Clinical usefulness of biochemical resorption markers in osteoporosis. ( De Vooght, K; Fairney, A; Kerkhoff, F; Kyd, PA; Thomas, E, 1999) |
| "The inhibitory effect of murine interferon gamma (muIFN gamma) on humoral hypercalcemia in nude mice bearing lower-jaw cancer (LJC-1-JCK), in which parathyroid-hormone(PTH)-related protein is responsible for causing humoral hypercalcemia by activating bone resorption, was examined in comparison with that of a new bisphosphonate, 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (alendronate)." | 3.69 | Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). ( Arita, H; Kakudo, S; Kasai, H; Tohkin, M, 1994) |
| "Galactosylhydroxylysine appears to be a sensitive index of bone resorption, useful in the clinical assessment of bone involvement and in the management of patients with mild primary hyperparathyroidism." | 3.69 | Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. ( Bertoldo, F; Bettica, P; Braga, V; LoCascio, V; Moro, L; Pasini, AF; Stefani, L, 1994) |
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 3.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| " Repeated SRT dosing did not significantly affect PK, although C 24h increased slightly." | 2.80 | Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women. ( Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M, 2015) |
| "Bisphosphonates inhibit bone resorption and may reduce this loss in BMD." | 2.80 | Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients. ( Jaroma, AV; Kröger, H; Soininvaara, TA, 2015) |
| "Whether denosumab fully inhibits bone resorption when challenged by a higher dose of teriparatide is unknown." | 2.80 | Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. ( Burnett-Bowie, SA; Foley, K; Leder, BZ; Lee, H; Neer, RM; Tsai, JN; Zhu, Y, 2015) |
| "However, their relative effects on bone resorption and formation, and how quickly the effects resolve after treatment cessation, are uncertain." | 2.79 | Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. ( Boonen, S; Deacon, S; Eastell, R; Kuwayama, T; Nagase, S; Ohyama, M; Small, M; Spector, T, 2014) |
| "The alendronate-treated cases had a reduced eroded surface (ES/BS, p<0." | 2.79 | Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae. ( Amling, M; Breer, S; Busse, B; Glueer, CC; Hahn, M; Hapfelmeier, A; Kornet, J; Krause, M; Morlock, M; Püschel, K; Soltau, M; Wulff, B; Zimmermann, EA, 2014) |
| " To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0." | 2.78 | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. ( Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K, 2013) |
| "Secondary outcomes included changes in bone resorption (betaCTX) and 12-month changes in BMD." | 2.75 | Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. ( Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B, 2010) |
| "Alendronate was effective in suppressing bone resorption and subsequent BMD decrease at the lumbar spine in patients with high-dose GC treatment." | 2.75 | Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. ( Funakawa, I; Funasaka, Y; Kaji, H; Kanda, F; Kuroki, Y; Murakawa, Y; Sugimoto, T, 2010) |
| "By reducing the bone resorption after implantation of a joint replacement, it should be possible to enhance the initial fixation of the implant." | 2.74 | Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. ( Aspenberg, P; Hansson, U; Ryd, L; Toksvig-Larsen, S, 2009) |
| "Alendronate was randomly prescribed for 41 patients and risedronate were prescribed for 43 patients." | 2.73 | Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. ( Iizuka, T; Matsukawa, M, 2008) |
| "Alendronate is a bisphosphonate frequently used to reduce bone resorption." | 2.73 | The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial. ( Cei, S; Gabriele, M; Graziani, F; La Ferla, F; Rosini, S, 2008) |
| "112 men with nonmetastatic prostate cancer receiving ADT." | 2.73 | Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. ( Greenspan, SL; Nelson, JB; Resnick, NM; Trump, DL, 2007) |
| "During the second year, the bone resorption marker, serum N-telopeptide, rose by 27% in the calcitriol group (P< or =0." | 2.72 | Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. ( Addesso, V; Cohen, A; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, P; Shane, E; Staron, RB, 2006) |
| "Alendronate treatment was associated with a 2." | 2.71 | Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. ( Ascott-Evans, BH; Guanabens, N; Kivinen, S; Magaril, CH; Melton, ME; Stuckey, BG; Stych, B; Vandormael, K, 2003) |
| "To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis." | 2.71 | Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. ( Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 2.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "Alendronate-treated patients sustained less bone loss at the spine than those in the reference group, and both intervention groups sustained less bone loss at the hip than the reference group." | 2.71 | Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. ( Addesso, V; Lo, SH; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, PB; Pardi, S; Shane, E; Staron, RB; Zucker, M, 2004) |
| "The alendronate effect was gender independent (P = 0." | 2.71 | Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. ( Biermasz, NR; Hamdy, NA; Pereira, AM; Roelfsema, F; Romijn, JA, 2004) |
| "Alendronate and calcium were generally safe and well tolerated." | 2.71 | Prevention of bone loss in paraplegics over 2 years with alendronate. ( Knecht, H; Kraenzlin, M; Lippuner, K; Michel, D; Perrelet, R; Risi, S; Zäch, GA; Zehnder, Y, 2004) |
| "We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women." | 2.71 | Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005) |
| "In contrast, bisphosphonates reduce bone resorption and increase BMD." | 2.70 | A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. ( Body, JJ; Correa-Rotter, R; Cumming, DC; Dore, RK; Gaich, GA; Hodsman, AB; Kulkarni, PM; Miller, PD; Papaioannou, A; Peretz, A; Scheele, WH, 2002) |
| "The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen." | 2.70 | Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. ( Adami, S; Bone, G; Foldes, AJ; Greenspan, SL; Kaur, A; Levine, MA; Orloff, JJ; Peverly, CA; Rizzoli, R; Roux, C; Santora, AC; Schnitzer, TJ; Uebelhart, B; Watts, NB, 2002) |
| "Alendronate is an effective, well-tolerated therapy for the prevention and treatment of glucocorticoid-induced osteoporosis, with sustained treatment advantages for up to 2 years." | 2.70 | Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. ( Adachi, JD; Block, JA; Brown, J; Carofano, W; Correa-Rotter, R; Czachur, M; Daifotis, A; Delmas, PD; Dumortier, T; Emkey, RD; Gruber, BL; Hawkins, F; Kaufman, JM; Lane, NE; Leite, MO; Liberman, UA; Malice, MP; McIlwain, HH; Melo-Gomes, JA; Menkes, CJ; Nevitt, MC; Poubelle, PE; Rodriguez-Portales, JA; Saag, KG; Schnitzer, TJ; Seeman, E; Sharp, JT; Siminoski, KG; Westhovens, R; Wing, J; Yanover, MJ, 2001) |
| "Alendronate (ALN) is an aminobisphosphonate commonly used for osteoporosis in postmenopausal women." | 2.70 | Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. ( Garay-Sevilla, ME; Malacara, JM; Nava, LE; Rocha, M; Sánchez-Márin, F; Vázquez de la Torre, C, 2001) |
| "Alendronate treatment did not impair bone mineralisation, induce the formation of woven bone or have any other adverse effects on bone quality." | 2.69 | The effects of alendronate on bone turnover and bone quality. ( Arlot, M; Chavassieux, P; Meunier, PJ; Yates, AJ, 1999) |
| "Alendronate seems to be a safe and effective nonhormonal option for prevention of postmenopausal bone loss." | 2.69 | Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. ( Clemmesen, B; Daifotis, A; Eisman, J; Gilchrist, NL; McClung, M; Ravn, P; Reda, C; Weinstein, RS; Yates, AJ, 1998) |
| "Biochemical markers of bone resorption included urinary N-telopeptide cross-linked collagen type I and free deoxypyridinoline; markers of bone formation included serum osteocalcin and bone-specific alkaline phosphatase." | 2.69 | Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. ( Ferguson, L; Greenspan, SL; Karpf, DB; Maitland-Ramsey, L; Parker, RA; Rosen, HN, 1998) |
| "Alendronate is an antiresorptive therapy for osteoporosis and results in a decrease in bone turnover." | 2.69 | Monitoring alendronate therapy for osteoporosis. ( Braga de Castro Machado, A; Eastell, R; Hannon, R, 1999) |
| "Alendronate has been shown to increase bone density among early postmenopausal women." | 2.69 | Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. ( Cizza, G; Ross, PD; Thompson, DE; Wasnich, RD; Yates, AJ, 1999) |
| "Osteoporosis is a frequent complication of rheumatoid arthritis (RA)." | 2.69 | Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. ( Acquista, CA; Cantatore, FP; Pipitone, V, 1999) |
| "Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated bone resorption." | 2.68 | Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. ( Emkey, RD; Kher, U; Peverly, CA; Santora, AC; Tonino, RP; Tucci, JR, 1996) |
| "Alendronate was generally well tolerated over all dosages." | 2.67 | Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. ( Chesnut, CH; Harris, ST, 1993) |
| " Subgroup analysis revealed that among the patients in the combination therapy group, greater increases in the spine BMD were observed when the PTH was administered with a dosage of 20 μg (WMD = 2." | 2.52 | Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. ( Chen, J; Fan, J; Gu, M; Li, B; Wang, C; Zhang, G, 2015) |
| "Inhibition of bone resorption is fully reversible following discontinuation." | 2.49 | Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. ( Josse, R; Khan, A; Ngui, D; Shapiro, M, 2013) |
| "Osteoporosis is characterized by a reduction in bone mineral density (BMD) ." | 2.47 | [New therapy using bisphosphonate for urolithiasis]. ( Hirose, M; Niimi, K; Yasui, T, 2011) |
| "Overactive bone resorption and limited bone formation lead to unstable combination between bone tissue and scaffolds." | 2.44 | An osteoporosis bone defect regeneration strategy via three-dimension short fibers loaded with alendronate modified hydroxyapatite. ( Cheng, Z; Dai, Z; Jia, W; Jiang, X; Jiao, K; Liu, G; Liu, L; Liu, Y; Luo, Y; Sun, M; Wang, H; Wang, S; Yang, T; Yang, Y, 2024) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.43 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005) |
| "Selection of appropriate drug for treatment of postmenopausal osteoporosis should take into account the long-term effect of the antiresorptive agent on bone." | 2.42 | Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. ( Alenfeld, F; Boivin, G; Feyen, JH; Lakatos, P; Stepan, JJ, 2003) |
| "Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure." | 2.42 | Postmenopausal osteoporosis and alendronate. ( Pérez-López, FR, 2004) |
| "Alendronate is an agent for the treatment of osteoporosis that has established safety with regards to bone quality since it neither inhibits bone calcification nor influences fracture healing in chronic administration." | 2.41 | [Pharmacological and clinical properties of alendronate sodium hydrate]. ( Komatsu, S; Ohta, T; Tokutake, N, 2002) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "This paper describes the rationale and supporting data for once-weekly dosing of alendronate." | 2.41 | Weekly administration of alendronate: rationale and plan for clinical assessment. ( Adami, S; Bone, HG; Daifotis, A; Favus, M; Orloff, J; Prahalada, S; Rizzoli, R; Ross, PD; Santora, A; Yates, J, 2000) |
| "The early inhibition of bone resorption induces a reduction in serum calcium which leads to increased parathyroid hormone (PTH), and subsequently an increase in 1,25-dihydroxyvitamin D." | 2.41 | Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001) |
| "Alendronate preferentially localises at bone resorption sites, where the drug inhibits osteoclastic activity." | 2.40 | Preclinical evidence of normal bone with alendronate. ( Hayes, WC; Rodan, GA; Shea, M, 1999) |
| "Many of the bisphosphonates inhibit bone resorption, the newest compounds being 10,000 times more active than etidronate, the first bisphosphonate described." | 2.40 | Bisphosphonates: preclinical aspects and use in osteoporosis. ( Fleisch, HA, 1997) |
| "They strongly inhibit bone resorption, but also strongly reduce bone formation." | 1.62 | Bisphosphonates impair the onset of bone formation at remodeling sites. ( Andersen, TL; Chavassieux, P; Delaisse, JM; Jensen, PR; Roux, JP, 2021) |
| "After a 2-week treatment, pain-related behavior was examined using von Frey filaments." | 1.56 | Functional Block of Interleukin-6 Reduces a Bone Pain Marker but Not Bone Loss in Hindlimb-Unloaded Mice. ( Kato, S; Miyamura, G; Nagao, N; Naito, Y; Sudo, A; Wakabayashi, H, 2020) |
| "Serum markers of bone formation, bone resorption, as well as bone mineral density (BMD) were serially measured." | 1.51 | Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women. ( Hao, C; Kang, L; Su, Z; Sun, Q; Tang, Y; Xia, H; Xue, Y, 2019) |
| "Osteoporosis is characterized by a progressive increase in bone fragility, leading to low bone mass and structural deterioration of bone tissue." | 1.51 | MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. ( Chu, C; Hao, W; Mao, Z; Su, H; Zhu, Y, 2019) |
| "Hajdu-Cheney syndrome (HCS) is a rare autosomal-dominant disorder primarily characterized by acro-osteolysis and early-onset osteoporosis." | 1.48 | High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome. ( Amling, M; Cornils, K; Fehse, B; Hermans-Borgmeyer, I; Jeschke, A; Oheim, R; Rolvien, T; Schinke, T; Triviai, I; Vollersen, N; Yorgan, TA, 2018) |
| "In order to determine the role of bone resorption in stress-mediated sutural bone growth, midpalatal suture expansion was performed in mice receiving alendronate, an anti-resorptive bisphosphonate." | 1.48 | Inhibition of bone resorption by bisphosphonates interferes with orthodontically induced midpalatal suture expansion in mice. ( Amling, M; Kahl-Nieke, B; Koehne, T; Korbmacher-Steiner, H, 2018) |
| "Bisphosphonates (BP) are inhibitors of bone resorption and are used to treat postmenopausal osteoporosis." | 1.48 | Healing of fractures in osteoporotic bones in mice treated with bisphosphonates - A transcriptome analysis. ( Hauser, M; Hofstetter, W; Keller, I; Siegrist, M, 2018) |
| "The frequency distribution of the bone resorption marker urinary deoxypyridinoline crosslinks (uDPD), was obtained retrospectively from 211 osteoporotic women attended at an academic hospital endocrine clinic, treated for >2 years with oral bisphosphonates." | 1.46 | BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD. ( Liel, Y; Plakht, Y; Tailakh, MA, 2017) |
| "Alendronate was also able to reduce marrow adiposity in both control diabetic mice compared to untreated mice." | 1.42 | Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. ( Baumann, MJ; Coe, LM; McCabe, LR; Shu, Y; Tekalur, SA, 2015) |
| "However, a limited amount of bone resorption is required for bisphosphonates to exert an effect." | 1.42 | Anti-RANKL treatment improves screw fixation in cancellous bone in rats. ( Aspenberg, P; Bernhardsson, M; Sandberg, O, 2015) |
| "Odanacatib (ODN) is a bone resorption inhibitor which differs from standard antiresorptives by its ability to reduce bone resorption without decreasing bone formation." | 1.40 | The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits. ( Andersen, TL; Delaissé, JM; Duong, LT; Jensen, PR; Pennypacker, BL, 2014) |
| "Treatment with alendronate, pamidronate, and zoledronate, but not clodronate, led to a decrease in the number of chondrocytes per column in the hypertrophic chondrocyte layer." | 1.40 | Effect of bisphosphonates on the rapidly growing male murine skeleton. ( Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED, 2014) |
| "Alendronate (ALN) is a potent inhibitor of osteoclastic bone resorption and results in reduced bone remodeling." | 1.40 | Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. ( de Blois, E; de Jong, M; Groen, HC; Koelewijn, SJ; Müller, C; Siebelt, M; Verhaar, JA; Waarsing, JH; Weinans, H, 2014) |
| "However, bone resorption was also stimulated by BMP; this stimulated bone resorption caused by BMP was effectively inhibited with addition of bisphosphonate." | 1.39 | Prefabrication of vascularized bone allograft in a recipient rat using a flow-through vascular pedicle, bone morphogenetic protein, and bisphosphonate. ( Imaizumi, Y; Kaji, Y; Nakamura, O; Yamagami, Y; Yamamoto, T, 2013) |
| "In addition, persons with high bone resorption in vitro on average had high levels of serum CTX." | 1.38 | Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. ( Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K, 2012) |
| " Since bisphosphonates may not only inhibit osteoclasts, but also osteoblasts and thus bone formation, we studied different bisphosphonate concentrations combined with allograft bone." | 1.38 | Impregnation of bone chips with alendronate and cefazolin, combined with demineralized bone matrix: a bone chamber study in goats. ( Bloem, RM; Buma, P; Hannink, G; Mathijssen, NM; Pilot, P; Schreurs, BW, 2012) |
| " A potent CatKI, L-006235 (L-235), dosed at 10 mg/kg per day for 27 weeks, significantly decreased LV BMD loss (p < ." | 1.37 | Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. ( Black, WC; Cusick, TE; Duong, LT; Gauthier, JY; Gentile, MA; Kimmel, DB; Masarachia, PJ; Pennypacker, BL; Samadfam, R; Scott, BB; Smith, SY, 2011) |
| "Alendronate treatment increased BMD and reduced the level of bone turnover markers." | 1.37 | Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis. ( Alimanovic-Alagić, R; Brković, A; Hadžović-Džuvo, A; Kučukalić-Selimović, E; Skopljak-Beganović, A; Valjevac, A, 2011) |
| "Osteoprotegerin (OPG) has also been shown to reduce osteoporotic changes in both humans and experimental animals after systemic administration." | 1.37 | Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. ( Chan, KM; Huang, P; Li, G; Tang, PF; Wang, Y, 2011) |
| "Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease." | 1.36 | Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| "Alendronate treatment enhanced bone thickness in TRPV5(+/+) mice but also normalized the disturbed bone morphometry parameters in TRPV5(-/-) mice." | 1.35 | Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice. ( Bindels, RJ; Hoenderop, JG; Nijenhuis, T; van der Eerden, BC; van Leeuwen, JP; Weinans, H, 2008) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| " These results suggest that by down-regulating MCP-1 and MIP-1alpha production via Smad3, long-term use of alendronate might inhibit normal activation and migration of osteoclasts and cause osteonecrosis." | 1.35 | Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation. ( Deng, X; Masuda, T; Tamai, R, 2009) |
| "Alendronate is a bisphosphonate that inhibits bone resorption, thereby increasing bone mineral density (BMD), while also reducing bone formation closely coupled with bone resorption." | 1.35 | Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. ( Aonuma, H; Hongo, M; Kasukawa, Y; Miyakoshi, N; Shimada, Y, 2009) |
| " We evaluated the effect of daily oral dosing of an inhibitor of human cathepsin K (SB-462795 [relacatib]) for 9 months on bone turnover, mass, and architecture in estrogen-deficient cynomolgus monkeys." | 1.35 | Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. ( Jerome, CP; Kumar, S; Stroup, GB, 2009) |
| "ALN suppressed trabecular bone resorption and endocortical bone erosion and formation and increased periosteal bone formation, while ALF increased the number of osteoblasts and suppressed trabecular bone resorption and markedly increased periosteal and endocortical bone formation." | 1.35 | Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. ( Iwamoto, J; K Yeh, J; Matsumoto, H; Sato, Y; Takeda, T, 2008) |
| "Alendronate treatment prevented much of the decrease in ultimate load that occurs in the first 21 days." | 1.34 | Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model. ( Gelberman, RH; Matsuzaki, H; Silva, MJ; Thomopoulos, S; Zaegel, M, 2007) |
| "Alendronate is a potent inhibitor of osteoclast-mediated bone resorption with no adverse effect on the mineralization of bone." | 1.34 | Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats. ( Altundal, H; Göker, K; Sayrak, H; Yurtsever, E, 2007) |
| "Treatment with alendronate reduced the width of the fibrous loosening membrane and the number of osteoclasts at the bone-screw interface." | 1.33 | Alendronate inhibits bone resorption at the bone-screw interface. ( Azuma, Y; Miyaji, T; Nakase, T; Shimizu, N; Uchiyama, Y; Yoshikawa, H, 2005) |
| " Twenty-four male Wistar rats at two months of age were castrated or sham-operated to evaluate the effects of long-term administration (six months) of sodium alendronate at a dose of 1 mg/kg/day." | 1.33 | Effect of alendronate administration on bone mineral density and bone strength in castrated rats. ( Broulik, PD; Rosenkrancová, J; Růzicka, P; Sedlácek, R, 2005) |
| " The weak affinity of clodronate translated into a requirement for 10-fold higher dosing in in vitro bone resorption assays when bone was pretreated with BP and subsequently washed prior to adding osteoclasts." | 1.33 | Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. ( Freedman, LP; Leu, CT; Luegmayr, E; Reszka, AA; Rodan, GA, 2006) |
| "Alendronate treatment of OPG-/- mice resulted in enhancement of the volume of heterotopic new bone." | 1.33 | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. ( Goto, S; Kameyama, Y; Kawai, T; Kimura, M; Maeda, H; Miyazawa, K; Tabuchi, M, 2005) |
| "This study investigates the role of bone resorption in defining interdigitations characteristic of cranial suture waveform." | 1.33 | Role of the osteoclast in cranial suture waveform patterning. ( Byron, CD, 2006) |
| "A total of 1,041 postmenopausal osteoporosis cases were classified into 4 categories, Young controls (n = 165) and Old controls (n = 95) (Control group), Young (n = 309) and Old osteoporosis (n = 110) treated with alendronate (ALN group), and Young (n = 238) and Old osteoporosis (n = 124) treated with vitamins D3 or K2 (VDK group)." | 1.33 | [Very old patients with osteoporosis should be treated with alendronate]. ( Shiraki, M, 2006) |
| "Hadju-Cheney syndrome is characterized by short stature, distinctive facies, and a slowly progressive skeletal dysplasia including acro-osteolysis." | 1.32 | Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients. ( Drake, WM; Hiorns, MP; Kendler, DL, 2003) |
| "When alendronate was injected at 3, 4, and 5 weeks, the bone mass increased by 70% and by 166% after 6 and 10 weeks, respectively, in comparison to the untreated control." | 1.32 | The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. ( Bahar, H; Binderman, I; Kollerman, R; Yaffe, A, 2003) |
| "Alendronate-treated rats showed less bone resorption, but etanercept, intermittent parathyroid hormone treatment, or saline did not reduce the fluid pressure-induced bone resorption." | 1.32 | A rat model for testing pharmacologic treatments of pressure-related bone loss. ( Aspenberg, P; Astrand, J; Skoglund, B; Skripitz, R, 2003) |
| "Alendronate was also effective in reducing bone loss as shown in previous reports." | 1.32 | Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats. ( Bahar, H; Binderman, I; Herman, A; Yaffe, A, 2003) |
| "Bone resorption was increased in patients with connective tissue disease and severe dystrophic calcification." | 1.32 | Increased bone resorption and failure to respond to antiresorptive therapy in progressive dystrophic calcification. ( Bresnihan, B; FitzGerald, O; Freaney, R; McKenna, M; Murphy, E, 2003) |
| "The alendronate or saline was administered subcutaneously 1 week prior to surgery, immediately prior to surgery, and 1 week after surgery." | 1.32 | A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible. ( Bostanci, H; Günhan, O; Kaynak, D; Meffert, R; Ozkaya, OG, 2003) |
| "Alendronate was significantly more effective than risedronate, calcitonin, estrogen, etidronate, and raloxifene (Relative Risks: 0." | 1.32 | Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. ( Hochberg, MC; Hosking, D; Wehren, LE, 2004) |
| "Alendronate use was also associated with a reduction in knee pain according to the WOMAC scores." | 1.32 | The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. ( Barrow, KD; Carbone, LD; Felson, D; Harris, F; Harris, TB; Kritchevsky, SB; Nevitt, MC; Peterfy, C; Visser, M; Wang, BW; Wildy, K, 2004) |
| "As revascularization follows, bone resorption may lead to collapse in load bearing areas during the remodeling." | 1.32 | Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats. ( Aspenberg, P; Astrand, J; Tägil, M; Westman, L, 2004) |
| "Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa." | 1.31 | Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). ( Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L, 2002) |
| "Because on bone marker measurement bone resorption was increased and bone formation was decreased from baseline, treatment was switched to oral alendronate (5 mg/day, daily)." | 1.31 | Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. ( Iwamoto, J; Takeda, T, 2002) |
| "Alendronate is a nitrogen-containing bisphosphonate analog used in the treatment of postmenopausal osteoporosis." | 1.31 | Alendronate stimulates collagenase 3 expression in osteoblasts by posttranscriptional mechanisms. ( Canalis, E; Varghese, S, 2000) |
| "Alendronate promotes apoptosis of the OCLs and it is related with the expression of the Fas gene." | 1.31 | Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. ( Wang, XM; Yang, ZP; Yu, SF, 2000) |
| " We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number." | 1.31 | Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. ( Halasy-Nagy, JM; Reszka, AA; Rodan, GA, 2001) |
| " The findings suggest that there is no pharmacodynamic advantage for continuous infusion of alendronate." | 1.31 | Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. ( Golomb, G; Hoffman, A; Stepensky, D, 2002) |
| "Alendronate is a pyrophosphate analogue of bisphosphonate that has been shown to inhibit osteoclastic bone resorption." | 1.31 | Alendronate does not inhibit early bone apposition to hydroxyapatite-coated total joint implants: a preliminary study. ( Akisue, T; Bauer, TW; Brown, PR; Mochida, Y, 2002) |
| "Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption." | 1.31 | Effects of alendronate on particle-induced osteolysis in a rat model. ( Allen, MJ; Bostrom, MP; Millett, PJ, 2002) |
| "Inhibition of bone resorption by alendronate was not, however, related to a decrease in osteoclast number." | 1.31 | Alendronate disturbs vesicular trafficking in osteoclasts. ( Alakangas, A; Halleen, J; Lehenkari, P; Mönkkönen, J; Mulari, M; Salo, J; Selander, K; Väänänen, K, 2002) |
| "Instability-induced bone resorption therefore seems to be reduced by bisphosphonates, but higher doses are needed to obtain this effect than to reduce bone resorption associated with normal remodeling of untraumatized bone." | 1.31 | Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. ( Aspenberg, P; Astrand, J, 2002) |
| "However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown." | 1.31 | Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. ( Bellido, T; Chen, JR; Jilka, RL; Landes, RD; Manolagas, SC; Parfitt, AM; Powers, CC; Stewart, SA; Weinstein, RS, 2002) |
| "When the inhibition of bone resorption by calcitonin, osteoprotegerin, or alendronate is combined with the acute inhibition of bone mineralization with etidronate, the BRC model correctly predicts that there will no longer be a sharp rise in calcium and phosphate, and, therefore, there will no longer be the formation of the fetuin-mineral complex." | 1.31 | Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. ( Caputo, JM; Price, PA; Williamson, MK, 2002) |
| "Bisphosphonates suppress bone resorption by inhibiting the activity of mature osteoclasts as well as the formation of osteoclasts from bone marrow-derived precursor cells." | 1.30 | Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. ( Löwik, CW; Papapoulos, SE; van Beek, ER, 1997) |
| "Alendronate treatment by itself decreased osteocalcin by day 28 and resulted in a marginal decrease in serum total calcium on day 14." | 1.30 | Alendronate prevents cyclosporin A-induced osteopenia in the rat. ( Bowman, AR; Epstein, S; Jee, WS; Ma, Y; Sass, DA; Yuan, Z, 1997) |
| "Two other markers of bone resorption, hydroxylysyl pyridinoline and lysyl pyridinoline, were found in peptide linkage in the culture medium but not in free form; indicating that the osteoclasts had degraded the bone collagen to peptides but not to the free cross-linking amino acids." | 1.30 | Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. ( Apone, S; Eyre, DR; Lee, MY, 1997) |
| "Based on evidence that the increased bone resorption after estrogen loss is due to an increase in osteoclastogenesis, we hypothesized that estrogen loss also stimulates osteoblastogenesis." | 1.30 | Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. ( Jilka, RL; Manolagas, SC; Munshi, M; Roberson, PK; Takahashi, K; Williams, DC, 1998) |
| "Aminobisphosphonates inhibit bone resorption but have been shown to elicit acute-phase-like elevations in interleukin-6 (IL-6) in bone in vitro." | 1.30 | Alendronate/interleukin-1beta cotreatment increases interleukin-6 in bone and UMR-106 cells: dose dependence and relationship to the antiresorptive effect of alendronate. ( Foster, SA; Sanders, JL; Stern, PH; Tarjan, G, 1998) |
| "When added to the medium, ALN inhibited bone resorption at concentrations < or =10(-7) M." | 1.30 | Human osteoclast formation and activity in vitro: effects of alendronate. ( Breuil, V; Cosman, F; Dempster, DW; Horbert, W; Lindsay, R; Nieves, J; Shen, V; Stein, L, 1998) |
| "Alendronate inhibition of bone resorption in mouse calvaria also is blocked by mevalonate whereas clodronate inhibition is not." | 1.30 | Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. ( Fisher, JE; Halasy, JM; Hughes, DE; Luckman, SP; Masarachia, PJ; Reszka, AA; Rodan, GA; Rogers, MJ; Russell, RG; Wesolowski, G, 1999) |
| "Alendronate is a bisphosphonate that can decrease osteoclastic activity." | 1.30 | Alendronate did not inhibit instability-induced bone resorption. A study in rats. ( Aspenberg, P; Astrand, J, 1999) |
| "Bisphosphonates can inhibit bone resorption and have been successfully used clinically to treat osteoporosis and Paget's disease." | 1.30 | Short-term effects of bisphosphonates on the biomechanical properties of canine bone. ( Agrawal, CM; Rubash, HE; Shanbhag, AS; Wang, X, 1999) |
| "The aim of the study was to assess the long-term anabolic effect of the parathyroid hormone (PTH) analog SDZ PTS 893 in a dose-response manner, and to determine the ability of the antiresorptive agents estradiol and alendronate to maintain bone mass after withdrawal of SDZ PTS 893." | 1.30 | Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. ( Gasser, JA; Mosekilde, LI; Thomsen, JS, 1999) |
| "All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%." | 1.29 | Acute effects of bisphosphonates on new and traditional markers of bone resorption. ( Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M, 1995) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Bone loss associated with postmenopausal osteoporosis can be reduced by treatment with antiresorptive agents such as estrogen or bisphosphonates." | 1.29 | Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. ( Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE, 1996) |
| "Alendronate inhibited bone resorption by isolated chicken or rat osteoclasts when the amount on the bone surface was around 1." | 1.28 | Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. ( Akins, R; Endo, N; Golub, E; Grasser, W; Rodan, GA; Sato, M; Simmons, H; Thompson, DD, 1991) |
| "It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroidectomized rats at a SC dose as low as 0." | 1.28 | BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. ( Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K, 1991) |
| "Alendronate was administered sc in doses of 0." | 1.28 | The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. ( Quartuccio, HA; Seedor, JG; Thompson, DD, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.27) | 18.7374 |
| 1990's | 79 (21.29) | 18.2507 |
| 2000's | 176 (47.44) | 29.6817 |
| 2010's | 98 (26.42) | 24.3611 |
| 2020's | 17 (4.58) | 2.80 |
| Authors | Studies |
|---|---|
| Szajnman, SH | 1 |
| Bailey, BN | 1 |
| Docampo, R | 1 |
| Rodriguez, JB | 1 |
| Szabo, CM | 2 |
| Matsumura, Y | 1 |
| Fukura, S | 1 |
| Martin, MB | 2 |
| Sanders, JM | 2 |
| Sengupta, S | 1 |
| Cieslak, JA | 1 |
| Loftus, TC | 1 |
| Lea, CR | 1 |
| Lee, HJ | 2 |
| Koohang, A | 1 |
| Coates, RM | 1 |
| Sagami, H | 1 |
| Oldfield, E | 4 |
| Widler, L | 1 |
| Jaeggi, KA | 1 |
| Glatt, M | 1 |
| Müller, K | 1 |
| Bachmann, R | 1 |
| Bisping, M | 1 |
| Born, AR | 1 |
| Cortesi, R | 1 |
| Guiglia, G | 1 |
| Jeker, H | 1 |
| Klein, R | 1 |
| Ramseier, U | 1 |
| Schmid, J | 1 |
| Schreiber, G | 1 |
| Seltenmeyer, Y | 1 |
| Green, JR | 1 |
| Song, Y | 1 |
| Chan, JM | 1 |
| Zhang, Y | 3 |
| Jennings, S | 1 |
| Kosztowski, T | 1 |
| Odeh, S | 1 |
| Flessner, R | 1 |
| Schwerdtfeger, C | 1 |
| Kotsikorou, E | 2 |
| Meints, GA | 1 |
| Gómez, AO | 1 |
| González-Pacanowska, D | 1 |
| Raker, AM | 1 |
| Wang, H | 2 |
| van Beek, ER | 3 |
| Papapoulos, SE | 3 |
| Morita, CT | 1 |
| Singh, US | 1 |
| Shankar, R | 1 |
| Kumar, A | 1 |
| Trivedi, R | 1 |
| Chattopadhyay, N | 1 |
| Shakya, N | 1 |
| Palne, S | 1 |
| Gupta, S | 1 |
| Hajela, K | 1 |
| Xie, H | 1 |
| Chen, G | 1 |
| Young, RN | 1 |
| Mounier, L | 1 |
| Morel, A | 1 |
| Ferrandez, Y | 1 |
| Morko, J | 1 |
| Vääräniemi, J | 1 |
| Gilardone, M | 1 |
| Roche, D | 1 |
| Cherfils, J | 1 |
| Blangy, A | 1 |
| Tsuda, E | 2 |
| Fukuda, C | 2 |
| Okada, A | 2 |
| Karibe, T | 1 |
| Hiruma, Y | 2 |
| Takagi, N | 1 |
| Isumi, Y | 1 |
| Yamamoto, T | 3 |
| Hasegawa, T | 2 |
| Uehara, S | 2 |
| Koide, M | 1 |
| Udagawa, N | 2 |
| Amizuka, N | 2 |
| Kumakura, S | 1 |
| de Faria, LP | 1 |
| Sueyoshi, G | 1 |
| de Oliveira, TC | 1 |
| Holliday, LS | 1 |
| Arana-Chavez, VE | 3 |
| Hadjiargyrou, M | 1 |
| Heo, J | 1 |
| Kim, M | 1 |
| Kim, JH | 1 |
| Shin, H | 1 |
| Lim, SE | 1 |
| Jung, HS | 1 |
| Sohn, Y | 1 |
| Ku, J | 1 |
| Larrañaga-Vera, A | 2 |
| Toti, KS | 2 |
| Flatow, JS | 2 |
| Haraczy, AJ | 2 |
| Warnick, E | 2 |
| Rao, H | 2 |
| Gao, ZG | 2 |
| Sussman, SM | 2 |
| Mediero, A | 2 |
| Leucht, P | 2 |
| Jacobson, KA | 2 |
| Cronstein, BN | 2 |
| Li, J | 3 |
| Zhang, R | 1 |
| Du, Y | 1 |
| Liu, G | 3 |
| Dong, Y | 1 |
| Zheng, M | 1 |
| Cui, W | 1 |
| Jia, P | 1 |
| Xu, Y | 1 |
| Yang, Y | 1 |
| Sun, M | 1 |
| Jia, W | 1 |
| Jiao, K | 1 |
| Wang, S | 1 |
| Liu, Y | 3 |
| Liu, L | 1 |
| Dai, Z | 1 |
| Jiang, X | 1 |
| Yang, T | 2 |
| Luo, Y | 1 |
| Cheng, Z | 1 |
| Silva, RAB | 1 |
| Sousa-Pereira, AP | 1 |
| Lucisano, MP | 1 |
| Romualdo, PC | 1 |
| Paula-Silva, FWG | 1 |
| Consolaro, A | 1 |
| Silva, LAB | 1 |
| Nelson-Filho, P | 1 |
| Kitasato, S | 2 |
| Tanaka, T | 2 |
| Chazono, M | 2 |
| Komaki, H | 1 |
| Kakuta, A | 1 |
| Inagaki, N | 1 |
| Akiyama, S | 1 |
| Marumo, K | 2 |
| Morita, A | 1 |
| Kobayashi, N | 2 |
| Choe, H | 2 |
| Ike, H | 1 |
| Tezuka, T | 1 |
| Higashihira, S | 1 |
| Inaba, Y | 2 |
| Sato, D | 1 |
| Takahata, M | 1 |
| Ota, M | 1 |
| Fujita, R | 1 |
| Iwasaki, N | 2 |
| Wakabayashi, H | 1 |
| Miyamura, G | 1 |
| Nagao, N | 1 |
| Kato, S | 1 |
| Naito, Y | 1 |
| Sudo, A | 1 |
| Sheng, H | 1 |
| Lao, Y | 1 |
| Zhang, S | 1 |
| Ding, W | 1 |
| Lu, D | 1 |
| Xu, B | 2 |
| Jensen, PR | 2 |
| Andersen, TL | 2 |
| Chavassieux, P | 3 |
| Roux, JP | 1 |
| Delaisse, JM | 2 |
| Shi, C | 1 |
| Sun, B | 1 |
| Ma, C | 1 |
| Wu, H | 1 |
| Chen, R | 1 |
| He, H | 1 |
| Nakagawa, Y | 1 |
| Mukai, S | 1 |
| Mori, K | 1 |
| Yabumoto, H | 1 |
| Nakamura, R | 1 |
| Shinya, Y | 1 |
| Yukizawa, Y | 1 |
| Kubota, S | 1 |
| Saito, T | 1 |
| Liel, Y | 1 |
| Plakht, Y | 1 |
| Tailakh, MA | 1 |
| Sequetto, PL | 1 |
| Gonçalves, RV | 1 |
| Pinto, AS | 1 |
| Oliveira, MGA | 1 |
| Maldonado, IRSC | 1 |
| Oliveira, TT | 1 |
| Novaes, RD | 1 |
| Vollersen, N | 1 |
| Hermans-Borgmeyer, I | 1 |
| Cornils, K | 1 |
| Fehse, B | 1 |
| Rolvien, T | 1 |
| Triviai, I | 1 |
| Jeschke, A | 1 |
| Oheim, R | 1 |
| Amling, M | 3 |
| Schinke, T | 1 |
| Yorgan, TA | 1 |
| Campbell, GM | 2 |
| Tower, RJ | 2 |
| Damm, T | 2 |
| Kneissl, P | 2 |
| Rambow, AC | 2 |
| Schem, C | 2 |
| Tiwari, S | 2 |
| Glüer, CC | 2 |
| Xie, Z | 1 |
| Tang, P | 1 |
| Sun, X | 1 |
| Chen, S | 1 |
| Qin, A | 2 |
| Zhu, P | 1 |
| Zhang, J | 1 |
| Fan, S | 1 |
| Koehne, T | 1 |
| Kahl-Nieke, B | 1 |
| Korbmacher-Steiner, H | 1 |
| Hauser, M | 1 |
| Siegrist, M | 1 |
| Keller, I | 1 |
| Hofstetter, W | 1 |
| Oršolić, N | 1 |
| Nemrava, J | 1 |
| Jeleč, Ž | 1 |
| Kukolj, M | 1 |
| Odeh, D | 1 |
| Terzić, S | 1 |
| Fureš, R | 1 |
| Bagatin, T | 1 |
| Bagatin, D | 1 |
| Tang, Y | 1 |
| Xia, H | 1 |
| Kang, L | 1 |
| Sun, Q | 1 |
| Su, Z | 1 |
| Hao, C | 1 |
| Xue, Y | 1 |
| Mao, Z | 1 |
| Zhu, Y | 2 |
| Hao, W | 1 |
| Chu, C | 1 |
| Su, H | 1 |
| Ji, WP | 1 |
| Wang, XL | 1 |
| Ma, MQ | 1 |
| Lan, J | 1 |
| Li, H | 1 |
| Nakamura, O | 1 |
| Kaji, Y | 1 |
| Imaizumi, Y | 1 |
| Yamagami, Y | 1 |
| Bradaschia-Correa, V | 2 |
| Moreira, MM | 2 |
| Jensen, TW | 1 |
| Hansen, MS | 1 |
| Hørslev-Petersen, K | 1 |
| Hyldstrup, L | 1 |
| Abrahamsen, B | 1 |
| Langdahl, B | 1 |
| Zerahn, B | 1 |
| Pødenphant, J | 1 |
| Stengaard-Petersen, K | 1 |
| Junker, P | 1 |
| Østergaard, M | 1 |
| Lottenburger, T | 1 |
| Ellingsen, T | 1 |
| Andersen, LS | 1 |
| Hansen, I | 1 |
| Skjødt, H | 1 |
| Pedersen, JK | 1 |
| Lauridsen, UB | 1 |
| Svendsen, AJ | 1 |
| Tarp, U | 1 |
| Lindegaard, H | 1 |
| Jurik, AG | 1 |
| Vestergaard, A | 1 |
| Hetland, ML | 1 |
| Yao, W | 2 |
| Guan, M | 1 |
| Jia, J | 1 |
| Dai, W | 1 |
| Lay, YA | 1 |
| Amugongo, S | 1 |
| Liu, R | 1 |
| Olivos, D | 1 |
| Saunders, M | 1 |
| Lam, KS | 1 |
| Nolta, J | 1 |
| Olvera, D | 1 |
| Ritchie, RO | 1 |
| Lane, NE | 2 |
| Casado-Gomez, I | 1 |
| Ferreira, LB | 1 |
| Boanini, E | 1 |
| Torricelli, P | 1 |
| Gazzano, M | 1 |
| Fini, M | 1 |
| Bigi, A | 1 |
| Eastell, R | 3 |
| Nagase, S | 2 |
| Small, M | 2 |
| Boonen, S | 1 |
| Spector, T | 1 |
| Ohyama, M | 2 |
| Kuwayama, T | 2 |
| Deacon, S | 2 |
| Lui, PP | 1 |
| Lee, YW | 1 |
| Mok, TY | 1 |
| Cheuk, YC | 1 |
| Wan, X | 1 |
| Zhao, Y | 1 |
| Burge, R | 1 |
| Jiang, Y | 1 |
| Boroujerdi, MA | 1 |
| Schmidt, S | 1 |
| Rhee, Y | 3 |
| Lee, EY | 1 |
| Lezcano, V | 2 |
| Ronda, AC | 1 |
| Condon, KW | 2 |
| Allen, MR | 3 |
| Plotkin, LI | 3 |
| Bellido, T | 4 |
| Pennypacker, BL | 2 |
| Duong, LT | 2 |
| Ikeda, T | 1 |
| Maruyama, K | 1 |
| Kaji, H | 2 |
| Akagi, M | 1 |
| Borm, JM | 1 |
| Moser, S | 1 |
| Locher, M | 1 |
| Damerau, G | 1 |
| Stadlinger, B | 1 |
| Grätz, KW | 1 |
| Jacobsen, C | 1 |
| Zhu, ED | 1 |
| Louis, L | 1 |
| Brooks, DJ | 1 |
| Bouxsein, ML | 1 |
| Demay, MB | 1 |
| Hashimoto, Y | 1 |
| Sharpe, J | 1 |
| Manako, J | 1 |
| Möller, B | 1 |
| Wiltfang, J | 1 |
| Acil, Y | 1 |
| Gierloff, M | 1 |
| Lippross, S | 1 |
| Terheyden, H | 1 |
| Frick, KK | 1 |
| Asplin, JR | 1 |
| Culbertson, CD | 1 |
| Granja, I | 1 |
| Krieger, NS | 2 |
| Bushinsky, DA | 2 |
| Tatara, AM | 1 |
| Lipner, JH | 1 |
| Das, R | 1 |
| Kim, HM | 1 |
| Patel, N | 1 |
| Ntouvali, E | 1 |
| Silva, MJ | 2 |
| Thomopoulos, S | 2 |
| Siebelt, M | 1 |
| Waarsing, JH | 1 |
| Groen, HC | 1 |
| Müller, C | 1 |
| Koelewijn, SJ | 1 |
| de Blois, E | 1 |
| Verhaar, JA | 1 |
| de Jong, M | 1 |
| Weinans, H | 2 |
| Duarte, JH | 1 |
| Assimos, DG | 1 |
| Huh, JE | 1 |
| Kim, SJ | 1 |
| Kang, JW | 1 |
| Nam, DW | 1 |
| Choi, DY | 1 |
| Park, DS | 1 |
| Lee, JD | 1 |
| Krause, M | 1 |
| Soltau, M | 1 |
| Zimmermann, EA | 1 |
| Hahn, M | 1 |
| Kornet, J | 1 |
| Hapfelmeier, A | 1 |
| Breer, S | 1 |
| Morlock, M | 1 |
| Wulff, B | 1 |
| Püschel, K | 1 |
| Glueer, CC | 1 |
| Busse, B | 1 |
| de Bakker, CM | 1 |
| Altman, AR | 1 |
| Tseng, WJ | 1 |
| Tribble, MB | 1 |
| Li, C | 1 |
| Chandra, A | 1 |
| Qin, L | 1 |
| Liu, XS | 1 |
| Coe, LM | 1 |
| Tekalur, SA | 1 |
| Shu, Y | 1 |
| Baumann, MJ | 1 |
| McCabe, LR | 1 |
| Jaroma, AV | 1 |
| Soininvaara, TA | 2 |
| Kröger, H | 1 |
| Bernhardsson, M | 2 |
| Sandberg, O | 2 |
| Aspenberg, P | 10 |
| Ochi, Y | 1 |
| Yamada, H | 1 |
| Mori, H | 1 |
| Kawada, N | 1 |
| Tanaka, M | 1 |
| Imagawa, A | 1 |
| Ohmoto, K | 1 |
| Kawabata, K | 1 |
| Khorasani, MS | 1 |
| Diko, S | 1 |
| Hsia, AW | 1 |
| Anderson, MJ | 1 |
| Genetos, DC | 1 |
| Haudenschild, DR | 1 |
| Christiansen, BA | 1 |
| Boskey, AL | 1 |
| Marino, J | 1 |
| Spevak, L | 1 |
| Pleshko, N | 1 |
| Doty, S | 1 |
| Carter, EM | 1 |
| Raggio, CL | 1 |
| Tsai, JN | 1 |
| Foley, K | 1 |
| Lee, H | 1 |
| Burnett-Bowie, SA | 1 |
| Neer, RM | 1 |
| Leder, BZ | 1 |
| Gortazar, AR | 1 |
| Davis, HM | 1 |
| Gabilondo, H | 1 |
| Maycas, M | 1 |
| Natsag, J | 1 |
| Kendall, MA | 1 |
| Sellmeyer, DE | 1 |
| McComsey, GA | 1 |
| Brown, TT | 1 |
| Wang, C | 1 |
| Zhang, G | 2 |
| Gu, M | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Li, B | 1 |
| Smith, SM | 3 |
| Heer, M | 1 |
| Shackelford, LC | 1 |
| Sibonga, JD | 1 |
| Spatz, J | 1 |
| Pietrzyk, RA | 1 |
| Hudson, EK | 1 |
| Zwart, SR | 1 |
| Muise, ES | 1 |
| Podtelezhnikov, AA | 1 |
| Pickarski, M | 1 |
| Loboda, A | 1 |
| Tan, Y | 1 |
| Hu, G | 1 |
| Thomspon, JR | 1 |
| Duong, le T | 1 |
| Tang, A | 1 |
| Qian, Y | 1 |
| Liu, S | 2 |
| Wang, W | 1 |
| Liang, G | 1 |
| Shao, J | 1 |
| Wang, Z | 1 |
| Fan, X | 1 |
| Ye, W | 1 |
| Desel, C | 1 |
| Heilmann, T | 1 |
| Fuchs, S | 1 |
| Zuhayra, M | 1 |
| Trauzold, A | 1 |
| Schott, S | 1 |
| Cattalini, JP | 1 |
| Roether, J | 1 |
| Hoppe, A | 1 |
| Pishbin, F | 1 |
| Haro Durand, L | 1 |
| Gorustovich, A | 1 |
| Boccaccini, AR | 1 |
| Lucangioli, S | 1 |
| Mouriño, V | 1 |
| Arai, R | 1 |
| Takahashi, D | 1 |
| Inoue, M | 1 |
| Irie, T | 1 |
| Asano, T | 1 |
| Konno, T | 1 |
| Terkawi, MA | 1 |
| Onodera, T | 1 |
| Kondo, E | 1 |
| Adami, S | 7 |
| Giannini, S | 1 |
| Bianchi, G | 1 |
| Sinigaglia, L | 1 |
| Di Munno, O | 1 |
| Fiore, CE | 1 |
| Minisola, S | 1 |
| Rossini, M | 2 |
| Nijenhuis, T | 1 |
| van der Eerden, BC | 1 |
| Hoenderop, JG | 1 |
| van Leeuwen, JP | 1 |
| Bindels, RJ | 1 |
| Thostenson, J | 1 |
| Weinstein, RS | 3 |
| Manolagas, SC | 3 |
| Iizuka, T | 1 |
| Matsukawa, M | 1 |
| Graziani, F | 1 |
| Rosini, S | 1 |
| Cei, S | 1 |
| La Ferla, F | 1 |
| Gabriele, M | 1 |
| Freundlich, M | 1 |
| Alon, US | 1 |
| Idris, AI | 1 |
| Greig, IR | 1 |
| Bassonga-Landao, E | 1 |
| Ralston, SH | 1 |
| van 't Hof, RJ | 1 |
| Husek, P | 1 |
| Svagera, Z | 1 |
| Vsianský, F | 1 |
| Franeková, J | 1 |
| Simek, P | 1 |
| Zikan, V | 1 |
| Stepan, JJ | 2 |
| Brookler, K | 1 |
| Schneider, JP | 1 |
| Hansson, U | 1 |
| Toksvig-Larsen, S | 1 |
| Ryd, L | 1 |
| Shomali, T | 1 |
| Rezaian, M | 1 |
| Rassouli, A | 1 |
| Asadi, F | 1 |
| Pluskiewicz, W | 1 |
| Adamczyk, P | 1 |
| Sawaryn, P | 1 |
| Boroń, A | 1 |
| Misiołek, M | 1 |
| Sosada, K | 1 |
| Drozdzowska, B | 1 |
| Ohishi, M | 1 |
| Chiusaroli, R | 1 |
| Ominsky, M | 1 |
| Asuncion, F | 1 |
| Thomas, C | 1 |
| Khatri, R | 1 |
| Kostenuik, P | 1 |
| Schipani, E | 1 |
| Agholme, F | 2 |
| Hikita, H | 1 |
| Miyazawa, K | 2 |
| Tabuchi, M | 2 |
| Kimura, M | 2 |
| Goto, S | 2 |
| Masuda, T | 1 |
| Deng, X | 1 |
| Tamai, R | 1 |
| Aonuma, H | 1 |
| Miyakoshi, N | 2 |
| Hongo, M | 1 |
| Kasukawa, Y | 1 |
| Shimada, Y | 1 |
| Saito, M | 1 |
| Kumagae, Y | 1 |
| Kikuchi, T | 2 |
| Keel, C | 1 |
| Kraenzlin, ME | 1 |
| Kraenzlin, CA | 1 |
| Müller, B | 1 |
| Meier, C | 1 |
| Nagayoshi, Y | 1 |
| Kawano, H | 1 |
| Sugiyama, S | 1 |
| Kuroda, Y | 1 |
| Ogawa, H | 1 |
| Stroup, GB | 1 |
| Kumar, S | 1 |
| Jerome, CP | 1 |
| Kuroki, Y | 1 |
| Murakawa, Y | 1 |
| Funakawa, I | 1 |
| Funasaka, Y | 1 |
| Kanda, F | 1 |
| Sugimoto, T | 1 |
| Paccou, J | 1 |
| Viget, N | 1 |
| Legrout-Gérot, I | 1 |
| Yazdanpanah, Y | 1 |
| Cortet, B | 1 |
| D'Amelio, P | 1 |
| Grimaldi, A | 1 |
| Cristofaro, MA | 1 |
| Ravazzoli, M | 1 |
| Molinatti, PA | 1 |
| Pescarmona, GP | 1 |
| Isaia, GC | 1 |
| Erickson, AM | 1 |
| Wang, X | 3 |
| Burr, DB | 2 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Oizumi, T | 1 |
| Funayama, H | 2 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 3 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 2 |
| Endo, Y | 3 |
| Cruz, L | 1 |
| Assumpção, E | 1 |
| Andrade, SF | 1 |
| Conrado, DJ | 1 |
| Kulkamp, IC | 1 |
| Guterres, SS | 1 |
| Pohlmann, AR | 1 |
| Tapaninen, TS | 1 |
| Venesmaa, PK | 1 |
| Jurvelin, JS | 2 |
| Miettinen, HJ | 2 |
| Kröger, HP | 1 |
| Schilcher, J | 1 |
| Fahlgren, A | 2 |
| Xiong, H | 1 |
| Wei, L | 1 |
| Hu, Y | 1 |
| Zhang, C | 3 |
| Peng, B | 1 |
| Pierroz, DD | 1 |
| Bonnet, N | 1 |
| Baldock, PA | 1 |
| Ominsky, MS | 1 |
| Stolina, M | 1 |
| Kostenuik, PJ | 1 |
| Ferrari, SL | 1 |
| Kim, CW | 1 |
| Yun, YP | 1 |
| Hwang, YS | 1 |
| Kwon, IK | 1 |
| Lee, SC | 1 |
| Fu, Q | 1 |
| Hu, SM | 1 |
| Yang, JJ | 1 |
| Hao, XJ | 1 |
| Zhu, B | 1 |
| Wang, Q | 1 |
| Wu, ZR | 1 |
| Cusick, TE | 1 |
| Masarachia, PJ | 2 |
| Gentile, MA | 1 |
| Gauthier, JY | 1 |
| Black, WC | 1 |
| Scott, BB | 1 |
| Samadfam, R | 2 |
| Smith, SY | 1 |
| Kimmel, DB | 1 |
| Aguirre, JI | 1 |
| Altman, MK | 1 |
| Vanegas, SM | 1 |
| Franz, SE | 1 |
| Bassit, AC | 1 |
| Wronski, TJ | 1 |
| Pozzi, S | 1 |
| Raje, N | 1 |
| Hussein, O | 1 |
| Tiedemann, K | 1 |
| Komarova, SV | 1 |
| Magnusson, P | 1 |
| Nistala, H | 1 |
| Lee-Arteaga, S | 1 |
| Carta, L | 1 |
| Cook, JR | 1 |
| Smaldone, S | 1 |
| Siciliano, G | 1 |
| Rifkin, AN | 1 |
| Dietz, HC | 1 |
| Rifkin, DB | 1 |
| Ramirez, F | 1 |
| Seeman, E | 2 |
| Giro, G | 1 |
| Coelho, PG | 1 |
| Pereira, RM | 1 |
| Jorgetti, V | 1 |
| Marcantonio, E | 1 |
| Orrico, SR | 1 |
| Kučukalić-Selimović, E | 1 |
| Valjevac, A | 1 |
| Hadžović-Džuvo, A | 1 |
| Skopljak-Beganović, A | 1 |
| Alimanovic-Alagić, R | 1 |
| Brković, A | 1 |
| Felsenberg, D | 3 |
| Bock, O | 1 |
| Börst, H | 1 |
| Armbrecht, G | 1 |
| Beller, G | 1 |
| Degner, C | 1 |
| Stephan-Oelkers, M | 1 |
| Schacht, E | 1 |
| Mazor, Z | 1 |
| Hashimoto, J | 1 |
| Roth, HJ | 1 |
| Martus, P | 1 |
| Runge, M | 1 |
| Won, HY | 1 |
| Lee, JA | 1 |
| Park, ZS | 1 |
| Song, JS | 1 |
| Kim, HY | 1 |
| Jang, SM | 1 |
| Yoo, SE | 1 |
| Hwang, ES | 1 |
| Bae, MA | 1 |
| Arrabal-Polo, MA | 1 |
| Arrabal-Martin, M | 1 |
| Zuluaga-Gomez, A | 1 |
| Inose, H | 1 |
| Zhou, B | 1 |
| Yadav, VK | 1 |
| Guo, XE | 1 |
| Karsenty, G | 1 |
| Ducy, P | 1 |
| Yoshitani, K | 1 |
| Kido, A | 1 |
| Honoki, K | 1 |
| Akahane, M | 1 |
| Fujii, H | 1 |
| Tanaka, Y | 1 |
| Wang, Y | 1 |
| Huang, P | 1 |
| Tang, PF | 1 |
| Chan, KM | 1 |
| Li, G | 1 |
| Yasui, T | 1 |
| Niimi, K | 1 |
| Hirose, M | 1 |
| Bollerslev, J | 1 |
| Marcocci, C | 1 |
| Sosa, M | 1 |
| Nordenström, J | 1 |
| Bouillon, R | 1 |
| Mosekilde, L | 1 |
| Nakayama, T | 2 |
| Mizoguchi, T | 1 |
| Yamashita, T | 2 |
| Kawahara, I | 1 |
| Kobayashi, Y | 1 |
| Moriyama, Y | 1 |
| Kurihara, S | 1 |
| Sahara, N | 1 |
| Ozawa, H | 1 |
| Takahashi, N | 1 |
| Heervä, E | 1 |
| Peltonen, S | 1 |
| Svedström, E | 1 |
| Aro, HT | 1 |
| Väänänen, K | 2 |
| Peltonen, J | 1 |
| Schousboe, JT | 1 |
| Bauer, DC | 1 |
| Mathijssen, NM | 1 |
| Hannink, G | 1 |
| Pilot, P | 1 |
| Schreurs, BW | 1 |
| Bloem, RM | 1 |
| Buma, P | 1 |
| Gasińska, T | 1 |
| Borowska, A | 1 |
| Wichary, H | 1 |
| Dec, R | 1 |
| Shane, E | 3 |
| Cohen, A | 2 |
| Stein, EM | 1 |
| McMahon, DJ | 3 |
| Young, P | 1 |
| Pandit, K | 1 |
| Staron, RB | 3 |
| Verna, EC | 1 |
| Brown, R | 1 |
| Restaino, S | 1 |
| Mancini, D | 3 |
| Toker, H | 1 |
| Ozdemir, H | 1 |
| Ozer, H | 1 |
| Eren, K | 1 |
| Song, K | 1 |
| Park, S | 1 |
| Park, HS | 1 |
| Lim, SK | 1 |
| Park, BW | 1 |
| Yoshioka, T | 1 |
| Okimoto, N | 1 |
| Okamoto, K | 1 |
| Sakai, A | 2 |
| Ohbayashi, Y | 1 |
| Miyake, M | 1 |
| Sawai, F | 1 |
| Minami, Y | 1 |
| Iwasaki, A | 1 |
| Matsui, Y | 2 |
| Josse, R | 1 |
| Khan, A | 1 |
| Ngui, D | 1 |
| Shapiro, M | 1 |
| Leblanc, A | 1 |
| Matsumoto, T | 1 |
| Jones, J | 1 |
| Shapiro, J | 1 |
| Lang, T | 1 |
| Shackelford, L | 1 |
| Evans, H | 1 |
| Spector, E | 1 |
| Ploutz-Snyder, R | 1 |
| Sibonga, J | 1 |
| Keyak, J | 1 |
| Nakamura, T | 2 |
| Kohri, K | 1 |
| Ohshima, H | 1 |
| Rubin, MR | 1 |
| Bilezikian, JP | 1 |
| Malnick, SD | 1 |
| Gottesfeld, F | 1 |
| Walpart, A | 1 |
| Keter, D | 1 |
| Lurie, Y | 1 |
| Beergabel, M | 1 |
| Cimaz, R | 1 |
| Gattorno, M | 1 |
| Sormani, MP | 1 |
| Falcini, F | 1 |
| Zulian, F | 1 |
| Lepore, L | 1 |
| Bardare, M | 1 |
| Chiesa, S | 1 |
| Corona, F | 1 |
| Dubini, A | 1 |
| Lenhardt, A | 1 |
| Martini, G | 1 |
| Masi, L | 1 |
| Bianchi, ML | 1 |
| Rodan, GA | 14 |
| Reszka, AA | 6 |
| Gulson, B | 1 |
| Mizon, K | 1 |
| Smith, H | 1 |
| Eisman, J | 2 |
| Palmer, J | 1 |
| Korsch, M | 1 |
| Donnelly, J | 1 |
| Waite, K | 1 |
| Body, JJ | 2 |
| Gaich, GA | 1 |
| Scheele, WH | 1 |
| Kulkarni, PM | 1 |
| Miller, PD | 3 |
| Peretz, A | 1 |
| Dore, RK | 1 |
| Correa-Rotter, R | 2 |
| Papaioannou, A | 1 |
| Cumming, DC | 1 |
| Hodsman, AB | 1 |
| Suomalainen, OT | 1 |
| Alhava, EM | 1 |
| Kröger, PJ | 1 |
| Greenspan, S | 2 |
| Field-Munves, E | 1 |
| Tonino, R | 1 |
| Smith, M | 1 |
| Petruschke, R | 1 |
| Wang, L | 1 |
| Yates, J | 2 |
| de Papp, AE | 2 |
| Palmisano, J | 1 |
| Hood, E | 1 |
| Rizzoli, R | 5 |
| Greenspan, SL | 4 |
| Bone, G | 1 |
| Schnitzer, TJ | 2 |
| Watts, NB | 1 |
| Foldes, AJ | 1 |
| Roux, C | 1 |
| Levine, MA | 1 |
| Uebelhart, B | 1 |
| Santora, AC | 3 |
| Kaur, A | 1 |
| Peverly, CA | 2 |
| Orloff, JJ | 1 |
| van der Poest Clement, E | 2 |
| van Engeland, M | 1 |
| Adèr, H | 1 |
| Roos, JC | 1 |
| Patka, P | 2 |
| Lips, P | 2 |
| Iwamoto, J | 5 |
| Takeda, T | 4 |
| Gómez-García, L | 1 |
| Esbrit, P | 1 |
| Carreño, L | 1 |
| Sabando, P | 1 |
| García-Flores, M | 1 |
| Martinez, ME | 1 |
| Drake, WM | 1 |
| Hiorns, MP | 1 |
| Kendler, DL | 1 |
| Ohta, T | 4 |
| Komatsu, S | 1 |
| Tokutake, N | 1 |
| Frith, JC | 2 |
| Rogers, MJ | 6 |
| Yaffe, A | 4 |
| Kollerman, R | 1 |
| Bahar, H | 2 |
| Binderman, I | 4 |
| Hayes, WC | 2 |
| Shea, M | 2 |
| Meunier, PJ | 2 |
| Arlot, M | 2 |
| Yates, AJ | 4 |
| Astrand, J | 4 |
| Skripitz, R | 1 |
| Skoglund, B | 1 |
| Ascott-Evans, BH | 1 |
| Guanabens, N | 1 |
| Kivinen, S | 1 |
| Stuckey, BG | 1 |
| Magaril, CH | 1 |
| Vandormael, K | 3 |
| Stych, B | 2 |
| Melton, ME | 2 |
| Ma, YL | 1 |
| Bryant, HU | 2 |
| Zeng, Q | 1 |
| Schmidt, A | 2 |
| Hoover, J | 1 |
| Cole, HW | 1 |
| Jee, WS | 2 |
| Sato, M | 3 |
| Srivastava, AK | 4 |
| Libanati, C | 2 |
| Oberrauch, W | 1 |
| Leenings, J | 1 |
| Greenwald, M | 1 |
| Baylink, DJ | 4 |
| Cosman, F | 2 |
| Herman, A | 1 |
| Murphy, E | 1 |
| Freaney, R | 1 |
| Bresnihan, B | 1 |
| McKenna, M | 1 |
| FitzGerald, O | 1 |
| Hosking, D | 2 |
| Andia, JC | 1 |
| Välimäki, M | 1 |
| Benhamou, L | 1 |
| Reginster, JY | 1 |
| Yacik, C | 1 |
| Rybak-Feglin, A | 1 |
| Petruschke, RA | 1 |
| Zaru, L | 1 |
| Glantschnig, H | 1 |
| Fisher, JE | 3 |
| Wesolowski, G | 3 |
| Aris, RM | 1 |
| Lester, GE | 1 |
| Caminiti, M | 1 |
| Blackwood, AD | 1 |
| Hensler, M | 1 |
| Lark, RK | 1 |
| Hecker, TM | 1 |
| Renner, JB | 1 |
| Guillen, U | 1 |
| Brown, SA | 1 |
| Neuringer, IP | 1 |
| Chalermskulrat, W | 1 |
| Ontjes, DA | 1 |
| Kaynak, D | 1 |
| Meffert, R | 1 |
| Bostanci, H | 1 |
| Günhan, O | 1 |
| Ozkaya, OG | 1 |
| Jeffery, JR | 1 |
| Leslie, WD | 1 |
| Karpinski, ME | 1 |
| Nickerson, PW | 1 |
| Rush, DN | 1 |
| Ichimura, S | 1 |
| Uzawa, M | 2 |
| Hannon, RA | 1 |
| Clowes, JA | 1 |
| Eagleton, AC | 1 |
| Al Hadari, A | 1 |
| Blumsohn, A | 1 |
| Addesso, V | 2 |
| Namerow, PB | 1 |
| Lo, SH | 1 |
| Zucker, M | 1 |
| Pardi, S | 1 |
| Maybaum, S | 2 |
| Lindsay, R | 3 |
| Kawata, T | 1 |
| Tenjou, K | 1 |
| Tokimasa, C | 1 |
| Fujita, T | 1 |
| Kaku, M | 1 |
| Matsuki, A | 1 |
| Kohno, S | 1 |
| Tsutsui, K | 1 |
| Ohtani, J | 1 |
| Motokawa, M | 1 |
| Shigekawa, M | 1 |
| Tohma, Y | 1 |
| Tanne, K | 1 |
| Harada, H | 1 |
| Nanaka, T | 1 |
| Katsumata, T | 1 |
| Saito, S | 1 |
| Nakatsuka, K | 1 |
| Okabe, R | 1 |
| Sohen, S | 1 |
| Sambrook, PN | 1 |
| Geusens, P | 1 |
| Ribot, C | 1 |
| Solimano, JA | 1 |
| Ferrer-Barriendos, J | 1 |
| Gaines, K | 1 |
| Verbruggen, N | 1 |
| Martin, TJ | 2 |
| Biermasz, NR | 1 |
| Hamdy, NA | 2 |
| Pereira, AM | 1 |
| Romijn, JA | 1 |
| Roelfsema, F | 1 |
| Alenfeld, F | 1 |
| Boivin, G | 2 |
| Feyen, JH | 1 |
| Lakatos, P | 1 |
| Wehren, LE | 1 |
| Hochberg, MC | 1 |
| Gutteridge, DH | 1 |
| Hoefle, G | 1 |
| Holzmueller, H | 1 |
| Drexel, H | 1 |
| Dejardin, A | 1 |
| Devogelaer, JP | 1 |
| Goffin, E | 1 |
| Zehnder, Y | 1 |
| Risi, S | 1 |
| Michel, D | 1 |
| Knecht, H | 1 |
| Perrelet, R | 1 |
| Kraenzlin, M | 1 |
| Zäch, GA | 1 |
| Lippuner, K | 1 |
| Pérez-López, FR | 1 |
| Viapiana, O | 1 |
| Gatti, D | 2 |
| Sato, Y | 3 |
| Carbone, LD | 1 |
| Nevitt, MC | 3 |
| Wildy, K | 1 |
| Barrow, KD | 1 |
| Harris, F | 2 |
| Felson, D | 1 |
| Peterfy, C | 1 |
| Visser, M | 1 |
| Harris, TB | 1 |
| Wang, BW | 1 |
| Kritchevsky, SB | 1 |
| Kasayama, S | 1 |
| Fujita, M | 1 |
| Goya, K | 1 |
| Yamamoto, H | 1 |
| Fujita, K | 1 |
| Morimoto, Y | 1 |
| Kawase, I | 1 |
| Miyatake, A | 1 |
| Agarwala, S | 1 |
| Jain, D | 1 |
| Joshi, VR | 1 |
| Sule, A | 1 |
| Odvina, CV | 1 |
| Zerwekh, JE | 2 |
| Rao, DS | 1 |
| Maalouf, N | 1 |
| Gottschalk, FA | 2 |
| Pak, CY | 2 |
| Isogai, Y | 1 |
| Miyaji, T | 1 |
| Nakase, T | 1 |
| Azuma, Y | 5 |
| Shimizu, N | 1 |
| Uchiyama, Y | 1 |
| Yoshikawa, H | 1 |
| Tascioglu, F | 1 |
| Colak, O | 1 |
| Armagan, O | 1 |
| Alatas, O | 1 |
| Oner, C | 1 |
| Rudge, S | 1 |
| Hailwood, S | 1 |
| Horne, A | 1 |
| Lucas, J | 1 |
| Wu, F | 1 |
| Cundy, T | 1 |
| Sebba, AI | 1 |
| Bonnick, SL | 1 |
| Kagan, R | 1 |
| Thompson, DE | 3 |
| Skalky, CS | 1 |
| Chen, E | 1 |
| Palomba, S | 1 |
| Orio, F | 1 |
| Russo, T | 1 |
| Falbo, A | 1 |
| Tolino, A | 1 |
| Manguso, F | 1 |
| Nunziata, V | 1 |
| Mastrantonio, P | 1 |
| Lombardi, G | 1 |
| Zullo, F | 1 |
| Pande, I | 1 |
| Hosking, DJ | 1 |
| Tägil, M | 1 |
| Westman, L | 1 |
| Ozdemir, F | 1 |
| Rodoplu, M | 1 |
| Recker, R | 1 |
| Masarachia, P | 2 |
| Santora, A | 2 |
| Howard, T | 1 |
| Rodan, G | 1 |
| Wehren, L | 1 |
| Kimmel, D | 1 |
| He, JH | 1 |
| Tong, NW | 1 |
| Li, HQ | 1 |
| Wu, J | 1 |
| Pitocco, D | 2 |
| Ruotolo, V | 2 |
| Caputo, S | 2 |
| Mancini, L | 2 |
| Collina, CM | 1 |
| Manto, A | 2 |
| Caradonna, P | 2 |
| Ghirlanda, G | 2 |
| Vaisman, DN | 1 |
| McCarthy, AD | 1 |
| Cortizo, AM | 1 |
| Ohsako, M | 1 |
| Monma, Y | 1 |
| Mayanagi, H | 1 |
| Scharla, S | 1 |
| Reichenhall, B | 1 |
| Onuma, E | 1 |
| Saito, H | 2 |
| Tsunenari, T | 1 |
| Watanabe, T | 1 |
| Hirabayashi, M | 1 |
| Sato, K | 2 |
| Yamada-Okabe, H | 1 |
| Ogata, E | 1 |
| Takada, J | 2 |
| Iba, K | 1 |
| Broulik, PD | 1 |
| Rosenkrancová, J | 1 |
| Růzicka, P | 1 |
| Sedlácek, R | 1 |
| Maricic, M | 1 |
| Rackoff, PJ | 1 |
| Sebba, A | 1 |
| Akahoshi, S | 1 |
| Arita, S | 1 |
| Ikeda, S | 1 |
| Morishita, Y | 1 |
| Tsutsumi, H | 1 |
| Ito, M | 2 |
| Shiraishi, A | 1 |
| Lee, JW | 1 |
| Jhee, O | 1 |
| Yuan, H | 1 |
| Kim, T | 1 |
| Kim, D | 1 |
| Lee, M | 1 |
| Om, A | 1 |
| Lee, B | 1 |
| Park, SK | 1 |
| Kang, J | 1 |
| Leu, CT | 2 |
| Luegmayr, E | 1 |
| Freedman, LP | 1 |
| Maeda, H | 1 |
| Kawai, T | 1 |
| Kameyama, Y | 1 |
| Menezes, AM | 1 |
| Rocha, FA | 1 |
| Chaves, HV | 1 |
| Carvalho, CB | 1 |
| Ribeiro, RA | 1 |
| Brito, GA | 1 |
| Binkley, N | 1 |
| Krueger, D | 1 |
| Kim, SW | 1 |
| Park, DJ | 1 |
| Park, KS | 1 |
| Kim, SY | 1 |
| Cho, BY | 1 |
| Lee, HK | 1 |
| Shin, CS | 1 |
| McClung, MR | 2 |
| Lewiecki, EM | 2 |
| Cohen, SB | 2 |
| Bolognese, MA | 2 |
| Woodson, GC | 1 |
| Moffett, AH | 1 |
| Peacock, M | 1 |
| Lederman, SN | 1 |
| Chesnut, CH | 3 |
| Lain, D | 1 |
| Kivitz, AJ | 1 |
| Holloway, DL | 1 |
| Peterson, MC | 1 |
| Bekker, PJ | 1 |
| Namerow, P | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Byron, CD | 1 |
| Arabmotlagh, M | 1 |
| Rittmeister, M | 1 |
| Hennigs, T | 1 |
| Iwata, K | 1 |
| Follet, H | 1 |
| Phipps, RJ | 1 |
| Shiraki, M | 1 |
| Asaba, Y | 1 |
| Hiramatsu, K | 1 |
| Harada, A | 1 |
| Nimura, Y | 1 |
| Katagiri, N | 1 |
| Kobayashi, T | 2 |
| Takewaka, T | 1 |
| Niida, S | 1 |
| Ikeda, K | 1 |
| Matsuzaki, H | 1 |
| Zaegel, M | 1 |
| Gelberman, RH | 1 |
| Altundal, H | 1 |
| Sayrak, H | 1 |
| Yurtsever, E | 1 |
| Göker, K | 1 |
| Heller, HJ | 1 |
| Jensen, TB | 2 |
| Bechtold, JE | 2 |
| Chen, X | 2 |
| Søballe, K | 2 |
| Saag, K | 1 |
| Kriegman, A | 1 |
| Beamer, E | 1 |
| Zhou, W | 1 |
| Nelson, JB | 1 |
| Trump, DL | 1 |
| Resnick, NM | 1 |
| Xia, Q | 1 |
| Goltzman, D | 1 |
| Nishioka, T | 1 |
| Yagi, S | 1 |
| Mitsuhashi, T | 1 |
| Miyamoto, M | 1 |
| Tamura, T | 1 |
| Enishi, T | 1 |
| Samanna, V | 1 |
| Ma, T | 1 |
| Mak, TW | 1 |
| Rogers, M | 1 |
| Chellaiah, MA | 1 |
| Lee, JI | 1 |
| Kim, HW | 1 |
| Wang, A | 1 |
| Siddhanti, S | 1 |
| Fitzpatrick, LA | 1 |
| Tankó, LB | 1 |
| Uchida, S | 1 |
| Taniguchi, T | 1 |
| Arizono, H | 1 |
| Shimizu, T | 1 |
| Okaniwa, M | 1 |
| Nakamura, K | 1 |
| Cesareo, R | 1 |
| Iozzino, M | 1 |
| Alva, D | 1 |
| Napolitano, C | 1 |
| De Rosa, B | 1 |
| Contini, S | 1 |
| Mallardo, L | 1 |
| Lauria, A | 1 |
| Reda, G | 1 |
| Orsini, A | 1 |
| Kidder, L | 1 |
| Collina, MC | 1 |
| Musella, T | 1 |
| Galli, M | 1 |
| Coxon, FP | 3 |
| Thompson, K | 1 |
| Roelofs, AJ | 1 |
| Ebetino, FH | 2 |
| Tanimoto, K | 1 |
| Okubo, Y | 1 |
| Harada, C | 1 |
| Sata, A | 1 |
| Nishikawa, A | 1 |
| Ohwada, R | 1 |
| Tsuiki, M | 1 |
| Hashimoto, E | 1 |
| Takano, K | 1 |
| Matsumoto, H | 1 |
| K Yeh, J | 1 |
| Tohkin, M | 1 |
| Kakudo, S | 1 |
| Kasai, H | 1 |
| Arita, H | 1 |
| Pedrazzoni, M | 1 |
| Alfano, FS | 1 |
| Gatti, C | 1 |
| Fantuzzi, M | 1 |
| Girasole, G | 1 |
| Campanini, C | 1 |
| Basini, G | 1 |
| Passeri, M | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 2 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 2 |
| Bikle, DD | 1 |
| Morey-Holton, ER | 1 |
| Doty, SB | 1 |
| Currier, PA | 1 |
| Tanner, SJ | 1 |
| Halloran, BP | 1 |
| LoCascio, V | 2 |
| Braga, V | 1 |
| Bertoldo, F | 2 |
| Bettica, P | 1 |
| Pasini, AF | 1 |
| Stefani, L | 1 |
| Moro, L | 1 |
| Zamberlan, N | 1 |
| Mian, M | 2 |
| Dorizzi, R | 1 |
| Braga, B | 1 |
| Gertz, BJ | 3 |
| Shao, P | 1 |
| Hanson, DA | 1 |
| Quan, H | 1 |
| Harris, ST | 2 |
| Genant, HK | 3 |
| Eyre, DR | 2 |
| Balena, R | 3 |
| Markatos, A | 2 |
| Seedor, JG | 4 |
| Gentile, M | 1 |
| Anderson, DC | 1 |
| Lauritzen, DB | 1 |
| Le, HM | 1 |
| Toolan, BC | 1 |
| Myers, ER | 1 |
| Nakamura, M | 1 |
| Shinoda, H | 1 |
| Takeda, Y | 1 |
| Nitta, Y | 1 |
| Kumagai, K | 1 |
| Sahni, M | 1 |
| Guenther, HL | 2 |
| Fleisch, H | 5 |
| Collin, P | 1 |
| Sansoni, P | 1 |
| Passeri, G | 1 |
| Fagnoni, F | 1 |
| Mohagheghpour, N | 1 |
| Snelli, G | 1 |
| Brianti, V | 1 |
| Engleman, EG | 1 |
| Rutledge, SJ | 1 |
| Endo, N | 2 |
| Opas, EE | 1 |
| Tanaka, H | 1 |
| Huang, Z | 1 |
| Ramachandaran, C | 1 |
| Rodan, SB | 1 |
| Vitté, C | 1 |
| Chokki, M | 1 |
| Antic, VN | 1 |
| Mühlbauer, RC | 2 |
| Busi, S | 1 |
| Catalano, A | 1 |
| Frolik, CA | 1 |
| Black, EC | 1 |
| Magee, DE | 1 |
| Chandrasekhar, S | 1 |
| Chilton, KM | 1 |
| Lawry, J | 1 |
| Smith, MO | 1 |
| Suri, S | 1 |
| Russell, RG | 2 |
| David, P | 1 |
| Nguyen, H | 1 |
| Barbier, A | 1 |
| Baron, R | 1 |
| Tucci, JR | 1 |
| Tonino, RP | 1 |
| Emkey, RD | 2 |
| Kher, U | 1 |
| Licata, AA | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Fleisch, HA | 1 |
| Löwik, CW | 2 |
| Bonde, M | 1 |
| Garnero, P | 1 |
| Fledelius, C | 1 |
| Qvist, P | 2 |
| Delmas, PD | 2 |
| Christiansen, C | 2 |
| Sass, DA | 1 |
| Bowman, AR | 1 |
| Yuan, Z | 1 |
| Ma, Y | 1 |
| Epstein, S | 1 |
| Dempster, DW | 2 |
| Apone, S | 1 |
| Lee, MY | 1 |
| Shanbhag, AS | 2 |
| Hasselman, CT | 1 |
| Rubash, HE | 2 |
| Iztkovich, M | 1 |
| Earon, Y | 1 |
| Alt, I | 1 |
| Lilov, R | 1 |
| McClung, M | 1 |
| Clemmesen, B | 1 |
| Daifotis, A | 4 |
| Gilchrist, NL | 1 |
| Reda, C | 1 |
| Ravn, P | 2 |
| Luckman, SP | 2 |
| Hughes, DE | 2 |
| Graham, R | 1 |
| Russell, G | 1 |
| Weisinger, JR | 1 |
| Alonzo, E | 1 |
| Machado, C | 1 |
| Carlini, R | 1 |
| Martinis, R | 1 |
| Paz-Martínez, V | 1 |
| Bellorín-Font, E | 1 |
| Jilka, RL | 2 |
| Takahashi, K | 1 |
| Munshi, M | 1 |
| Williams, DC | 1 |
| Roberson, PK | 1 |
| Cohen, H | 1 |
| Solomon, V | 1 |
| Alferiev, IS | 1 |
| Breuer, E | 2 |
| Ornoy, A | 1 |
| Patlas, N | 1 |
| Eidelman, N | 1 |
| Hägele, G | 1 |
| Golomb, G | 3 |
| Sanders, JL | 1 |
| Tarjan, G | 1 |
| Foster, SA | 1 |
| Stern, PH | 1 |
| Erlebacher, A | 1 |
| Filvaroff, EH | 1 |
| Ye, JQ | 1 |
| Derynck, R | 1 |
| Zaidi, M | 1 |
| Clemens, JD | 1 |
| Holland, SD | 1 |
| Yuan, W | 1 |
| Rosen, CJ | 1 |
| Parker, RA | 2 |
| Ferguson, L | 1 |
| Rosen, HN | 2 |
| Maitland-Ramsey, L | 1 |
| Karpf, DB | 2 |
| Peter, CP | 1 |
| Handt, LK | 1 |
| Fradinger, EE | 1 |
| Rodriguez, G | 1 |
| Bogado, C | 1 |
| Zanchetta, JR | 1 |
| Breuil, V | 1 |
| Stein, L | 1 |
| Horbert, W | 1 |
| Nieves, J | 1 |
| Shen, V | 1 |
| Halasy, JM | 1 |
| Neumann, KJ | 1 |
| Asplin, J | 1 |
| Braga de Castro Machado, A | 1 |
| Hannon, R | 1 |
| Lombardi, A | 2 |
| Agrawal, CM | 1 |
| Kyd, PA | 1 |
| De Vooght, K | 1 |
| Kerkhoff, F | 1 |
| Thomas, E | 1 |
| Fairney, A | 1 |
| Pinto, T | 1 |
| Alexandersen, P | 2 |
| Møllgaard, A | 1 |
| Wasnich, RD | 1 |
| Ross, PD | 3 |
| Cizza, G | 1 |
| Pols, HA | 1 |
| Hanley, DA | 1 |
| Stepán, J | 1 |
| Muñoz-Torres, M | 1 |
| Wilkin, TJ | 1 |
| Qin-sheng, G | 1 |
| Galich, AM | 1 |
| Cantatore, FP | 1 |
| Acquista, CA | 1 |
| Pipitone, V | 1 |
| Chapman, B | 1 |
| Thomsen, JS | 1 |
| Mosekilde, LI | 1 |
| Gasser, JA | 1 |
| Palermo, L | 1 |
| Musliner, T | 1 |
| Kleerekoper, M | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Bone, HG | 1 |
| Favus, M | 1 |
| Prahalada, S | 1 |
| Orloff, J | 1 |
| Antoniou, J | 1 |
| Huk, O | 1 |
| Zukor, D | 1 |
| Eyre, D | 1 |
| Alini, M | 1 |
| Haarman, H | 1 |
| Christgau, S | 2 |
| Bitsch-Jensen, O | 1 |
| Hanover Bjarnason, N | 1 |
| Gamwell Henriksen, E | 1 |
| Bang Henriksen, D | 1 |
| Grove, JE | 1 |
| Brown, RJ | 1 |
| Watts, DJ | 1 |
| Fink, E | 1 |
| Cormier, C | 1 |
| Steinmetz, P | 1 |
| Kindermans, C | 1 |
| Le Bouc, Y | 1 |
| Souberbielle, JC | 1 |
| Bhattacharyya, S | 1 |
| Castillo, G | 1 |
| Mohan, S | 2 |
| Varghese, S | 1 |
| Canalis, E | 1 |
| Adachi, JD | 1 |
| Saag, KG | 1 |
| Liberman, UA | 1 |
| Kaufman, JM | 1 |
| Poubelle, PE | 1 |
| Hawkins, F | 1 |
| Menkes, CJ | 1 |
| Rodriguez-Portales, JA | 1 |
| Block, JA | 1 |
| Wing, J | 1 |
| McIlwain, HH | 1 |
| Westhovens, R | 1 |
| Brown, J | 1 |
| Melo-Gomes, JA | 1 |
| Gruber, BL | 1 |
| Yanover, MJ | 1 |
| Leite, MO | 1 |
| Siminoski, KG | 1 |
| Sharp, JT | 1 |
| Malice, MP | 1 |
| Dumortier, T | 1 |
| Czachur, M | 1 |
| Carofano, W | 1 |
| Rocha, M | 1 |
| Nava, LE | 1 |
| Vázquez de la Torre, C | 1 |
| Sánchez-Márin, F | 1 |
| Garay-Sevilla, ME | 1 |
| Malacara, JM | 1 |
| Wang, XM | 1 |
| Yu, SF | 1 |
| Yang, ZP | 1 |
| Payer, J | 1 |
| Killinger, Z | 1 |
| Masaryk, P | 1 |
| Tomková, S | 1 |
| Kmecová, Z | 1 |
| Ondrejková, J | 1 |
| Necas, L | 1 |
| Smoterová, J | 1 |
| Ondrejka, P | 1 |
| Kratochvilová, H | 1 |
| Price, PA | 2 |
| Faus, SA | 1 |
| Williamson, MK | 2 |
| Mönkkönen, J | 2 |
| Auriola, S | 1 |
| Mönkkönen, H | 1 |
| Halasy-Nagy, JM | 1 |
| Vasikaran, SD | 1 |
| MacFarlane, G | 1 |
| Srivastava, VP | 1 |
| Yang, Z | 1 |
| Yu, S | 1 |
| Stepensky, D | 1 |
| Hoffman, A | 1 |
| Mochida, Y | 1 |
| Bauer, TW | 1 |
| Akisue, T | 1 |
| Brown, PR | 1 |
| Millett, PJ | 1 |
| Allen, MJ | 1 |
| Bostrom, MP | 1 |
| Lane, N | 1 |
| Cummings, SR | 1 |
| Ensrud, K | 1 |
| LaCroix, AZ | 1 |
| Black, DM | 1 |
| Alakangas, A | 1 |
| Selander, K | 1 |
| Mulari, M | 1 |
| Halleen, J | 1 |
| Lehenkari, P | 1 |
| Salo, J | 1 |
| Chen, JR | 1 |
| Powers, CC | 1 |
| Stewart, SA | 1 |
| Landes, RD | 1 |
| Parfitt, AM | 1 |
| Inaba, M | 1 |
| Ringe, JD | 1 |
| Orwoll, E | 1 |
| Lehmann, HJ | 1 |
| Mouritzen, U | 1 |
| Cloos, PA | 1 |
| Kim, YH | 1 |
| Kim, GS | 1 |
| Jeong-Hwa, B | 1 |
| Caputo, JM | 1 |
| Zysset, E | 1 |
| Ammann, P | 1 |
| Jenzer, A | 1 |
| Portmann, L | 1 |
| Jaquet-Müller, F | 1 |
| Pryor-Tillotson, S | 1 |
| Bonjour, JP | 2 |
| Burckhardt, P | 1 |
| Buchs, B | 1 |
| Nemoto, R | 1 |
| Satou, S | 1 |
| Mochizuki, T | 1 |
| Grasser, W | 3 |
| Akins, R | 1 |
| Simmons, H | 1 |
| Thompson, DD | 3 |
| Golub, E | 1 |
| Rosenblatt, M | 1 |
| Bauss, F | 1 |
| Schenk, R | 1 |
| Janner, M | 1 |
| Bosies, E | 1 |
| Strein, K | 1 |
| Quartuccio, HA | 1 |
| O'Doherty, DP | 1 |
| Bickerstaff, DR | 1 |
| McCloskey, EV | 1 |
| Beneton, MN | 1 |
| Harris, S | 1 |
| Kanis, JA | 1 |
| Kozak, S | 1 |
| Trechsel, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis[NCT00532337] | Phase 2 | 285 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty[NCT04167163] | Phase 4 | 58 participants (Actual) | Interventional | 2020-01-10 | Active, not recruiting | ||
| Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption[NCT01750086] | Phase 4 | 27 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation[NCT00297830] | Phase 2/Phase 3 | 111 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant[NCT00580047] | 59 participants (Actual) | Interventional | 2003-12-01 | Completed | |||
| Efficacy and Safety of Minodronate in the Treatment of Postmenopausal Osteoporosis With Low Back Pain: a Single-centre and Randomized Controlled Trial[NCT05645289] | Phase 4 | 72 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients[NCT00157690] | Phase 4 | 56 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Prevention of Osteoporosis After Cardiac Transplantation[NCT00000412] | Phase 3 | 149 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study[NCT01360099] | 120 participants (Actual) | Observational | 2011-05-04 | Completed | |||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| Efficacy of Treatment With DENOsumab of an Acute CHARCOT Foot in Patients With Diabetes. A Multicenter, Double-blind, Randomized, Placebo-controlled Trial.[NCT04547348] | Phase 3 | 38 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density[NCT00043186] | Phase 2 | 412 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| A Phase III, Randomized, Two-armed, Parallel, Double-blind, Active-controlled, Non-inferiority Clinical Trial to Determine the Non-inferior Therapeutic Efficacy and Safety Between Arylia (60 mg, Denosumab, Produced by AryoGen Pharmed) Compared With Prolia[NCT03293108] | Phase 3 | 190 participants (Anticipated) | Interventional | 2017-04-29 | Active, not recruiting | ||
| Prevention of Osteoporosis in Men With Prostate Cancer[NCT00048841] | Phase 3 | 112 participants | Interventional | 2002-05-31 | Completed | ||
| Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis[NCT00145977] | 36 participants (Actual) | Interventional | 2001-07-31 | Completed | |||
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8. (NCT01750086)
Timeframe: 8 weeks
| Intervention | percentage of change in CTX (Mean) |
|---|---|
| Denosumab 60mg Subcutaneous Injection | -7 |
| Alendronate 70mg Weekly x 8 Weeks | 43 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 0.28 |
| Placebo Zoledronic Acid and Active Alendronate | -0.57 |
| Reference Group | -3.3 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 1.98 |
| Placebo Zoledronic Acid and Active Alendronate | -0.45 |
| Reference Group | -2.6 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 0.39 |
| Placebo Zoledronic Acid and Active Alendronate | -0.21 |
| Reference Group | -2.2 |
Compare compliance where a study coordinator interviewed patients as to how often they missed the once a week oral alendronate, missed taking calcium and vitamin D supplementation, or missed the once a year IV Reclast. (NCT00580047)
Timeframe: 24 months
| Intervention | percentage of compliance (Number) |
|---|---|
| Intravenous Bisphosphonate Post Transplantation | 100 |
| Oral Bisphosphonate Post Transplantation | 80 |
| Placebo Group Post Transplantation | 80 |
Posterior Anterior (PA) spine bone density was measured by dual energy x-ray absorptiometry (DXA) at baseline and 24 months post transplant. The percentage change in the PA spine bone density was then compared from baseline to 24 months post transplant. (NCT00580047)
Timeframe: 24 months
| Intervention | percentage of change of bone density (Number) |
|---|---|
| Intravenous Bisphosphonate Post Transplantation | 8.1 |
| Oral Bisphosphonate Post Transplantation | 6.6 |
| Placebo Group Post Transplantation | 6.5 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -4.609 |
| Denosumab 6 mg Q3M | -62.716 |
| Denosumab 14 mg Q3M | -60.098 |
| Denosumab 30 mg Q3M | -70.256 |
| Denosumab 14 mg Q6M | -39.474 |
| Denosumab 60 mg Q6M | -65.215 |
| Denosumab 100 mg Q6M | -61.979 |
| Denosumab 210 mg Q6M | -67.634 |
| Alendronate 70 mg | -61.059 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 16.464 |
| Denosumab 6 mg Q3M | -41.225 |
| Denosumab 14 mg Q3M | -47.597 |
| Denosumab 30 mg Q3M | -57.905 |
| Denosumab 14 mg Q6M | -22.350 |
| Denosumab 60 mg Q6M | -43.448 |
| Denosumab 100 mg Q6M | -50.176 |
| Denosumab 210 mg Q6M | -48.833 |
| Alendronate 70 mg | -48.778 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 1.955 |
| Denosumab 6 mg Q3M | -39.012 |
| Denosumab 14 mg Q3M | -56.021 |
| Denosumab 30 mg Q3M | 22.343 |
| Denosumab 14 mg Q6M | -47.500 |
| Denosumab 60 mg Q6M | -42.541 |
| Denosumab 100 mg Q6M | -47.418 |
| Denosumab 210 mg Q6M | 61.747 |
| Alendronate 70 mg | -8.209 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 1.288 |
| Denosumab 6 mg Q3M | -40.182 |
| Denosumab 14 mg Q3M | -40.819 |
| Denosumab 30 mg Q3M | -52.684 |
| Denosumab 14 mg Q6M | -53.763 |
| Denosumab 60 mg Q6M | -44.892 |
| Denosumab 100 mg Q6M | -48.303 |
| Denosumab 210 mg Q6M | 17.841 |
| Alendronate 70 mg | -22.069 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 18.122 |
| Denosumab 6 mg Q3M | -34.727 |
| Denosumab 14 mg Q3M | -45.779 |
| Denosumab 30 mg Q3M | -47.770 |
| Denosumab 14 mg Q6M | -46.286 |
| Denosumab 60 mg Q6M | -34.361 |
| Denosumab 100 mg Q6M | -42.653 |
| Denosumab 210 mg Q6M | 21.053 |
| Alendronate 70 mg | -17.891 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.97 |
| Denosumab 6 mg Q3M | 0.89 |
| Denosumab 14 mg Q3M | 0.40 |
| Denosumab 30 mg Q3M | 1.10 |
| Denosumab 14 mg Q6M | 0.94 |
| Denosumab 60 mg Q6M | 1.29 |
| Denosumab 100 mg Q6M | 1.07 |
| Denosumab 210 mg Q6M | 1.09 |
| Alendronate 70 mg | -0.53 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.78 |
| Denosumab 6 mg Q3M | 1.31 |
| Denosumab 14 mg Q3M | 0.62 |
| Denosumab 30 mg Q3M | 1.30 |
| Denosumab 14 mg Q6M | 2.48 |
| Denosumab 60 mg Q6M | 1.89 |
| Denosumab 100 mg Q6M | 1.48 |
| Denosumab 210 mg Q6M | 0.81 |
| Alendronate 70 mg | -0.78 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -3.64 |
| Denosumab 6 mg Q3M | 1.99 |
| Denosumab 14 mg Q3M | 1.06 |
| Denosumab 30 mg Q3M | 1.05 |
| Denosumab 14 mg Q6M | 2.08 |
| Denosumab 60 mg Q6M | 2.69 |
| Denosumab 100 mg Q6M | 1.92 |
| Denosumab 210 mg Q6M | 0.12 |
| Alendronate 70 mg | -0.95 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -6.59 |
| Denosumab 6 mg Q3M | 1.00 |
| Denosumab 14 mg Q3M | 0.82 |
| Denosumab 30 mg Q3M | -3.91 |
| Denosumab 14 mg Q6M | 1.29 |
| Denosumab 60 mg Q6M | -0.87 |
| Denosumab 100 mg Q6M | 0.02 |
| Denosumab 210 mg Q6M | 0.59 |
| Alendronate 70 mg | -3.32 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -4.67 |
| Denosumab 6 mg Q3M | 1.04 |
| Denosumab 14 mg Q3M | 1.42 |
| Denosumab 30 mg Q3M | 1.77 |
| Denosumab 14 mg Q6M | 1.74 |
| Denosumab 60 mg Q6M | 1.71 |
| Denosumab 100 mg Q6M | 1.37 |
| Denosumab 210 mg Q6M | -0.94 |
| Alendronate 70 mg | -2.67 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Alendronate 70 mg | 4.59 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.81 |
| Denosumab 6 mg Q3M | 4.41 |
| Denosumab 14 mg Q3M | 4.71 |
| Denosumab 30 mg Q3M | 6.69 |
| Denosumab 14 mg Q6M | 3.03 |
| Denosumab 60 mg Q6M | 4.55 |
| Denosumab 100 mg Q6M | 5.52 |
| Denosumab 210 mg Q6M | 5.07 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.25 |
| Denosumab 6 mg Q3M | 7.42 |
| Denosumab 14 mg Q3M | 7.21 |
| Denosumab 30 mg Q3M | 8.83 |
| Denosumab 14 mg Q6M | 3.94 |
| Denosumab 60 mg Q6M | 7.19 |
| Denosumab 100 mg Q6M | 7.31 |
| Denosumab 210 mg Q6M | 7.86 |
| Alendronate 70 mg | 6.09 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.80 |
| Denosumab 6 mg Q3M | 8.57 |
| Denosumab 14 mg Q3M | 9.17 |
| Denosumab 30 mg Q3M | 1.94 |
| Denosumab 14 mg Q6M | 7.99 |
| Denosumab 60 mg Q6M | 9.04 |
| Denosumab 100 mg Q6M | 10.63 |
| Denosumab 210 mg Q6M | 0.85 |
| Alendronate 70 mg | 4.70 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 1.09 |
| Denosumab 6 mg Q3M | 7.21 |
| Denosumab 14 mg Q3M | 10.04 |
| Denosumab 30 mg Q3M | 5.06 |
| Denosumab 14 mg Q6M | 9.46 |
| Denosumab 60 mg Q6M | 9.59 |
| Denosumab 100 mg Q6M | 9.99 |
| Denosumab 210 mg Q6M | 1.06 |
| Alendronate 70 mg | 6.51 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.39 |
| Denosumab 6 mg Q3M | 9.35 |
| Denosumab 14 mg Q3M | 9.93 |
| Denosumab 30 mg Q3M | 9.03 |
| Denosumab 14 mg Q6M | 10.10 |
| Denosumab 60 mg Q6M | 10.34 |
| Denosumab 100 mg Q6M | 11.76 |
| Denosumab 210 mg Q6M | 2.50 |
| Alendronate 70 mg | 4.54 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -4.699 |
| Denosumab 6 mg Q3M | -61.366 |
| Denosumab 14 mg Q3M | -77.989 |
| Denosumab 30 mg Q3M | -87.238 |
| Denosumab 14 mg Q6M | -12.054 |
| Denosumab 60 mg Q6M | -70.757 |
| Denosumab 100 mg Q6M | -78.617 |
| Denosumab 210 mg Q6M | -84.107 |
| Alendronate 70 mg | -72.603 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -5.940 |
| Denosumab 6 mg Q3M | -50.687 |
| Denosumab 14 mg Q3M | -74.078 |
| Denosumab 30 mg Q3M | -83.985 |
| Denosumab 14 mg Q6M | -8.467 |
| Denosumab 60 mg Q6M | -68.437 |
| Denosumab 100 mg Q6M | -80.460 |
| Denosumab 210 mg Q6M | -85.680 |
| Alendronate 70 mg | -69.386 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -16.577 |
| Denosumab 6 mg Q3M | -62.298 |
| Denosumab 14 mg Q3M | -53.643 |
| Denosumab 30 mg Q3M | 56.286 |
| Denosumab 14 mg Q6M | -57.500 |
| Denosumab 60 mg Q6M | -54.418 |
| Denosumab 100 mg Q6M | -45.057 |
| Denosumab 210 mg Q6M | 72.135 |
| Alendronate 70 mg | -33.982 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -16.279 |
| Denosumab 6 mg Q3M | -63.543 |
| Denosumab 14 mg Q3M | -40.827 |
| Denosumab 30 mg Q3M | -62.334 |
| Denosumab 14 mg Q6M | -46.408 |
| Denosumab 60 mg Q6M | -57.255 |
| Denosumab 100 mg Q6M | -56.377 |
| Denosumab 210 mg Q6M | 33.999 |
| Alendronate 70 mg | -46.743 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -14.561 |
| Denosumab 6 mg Q3M | -40.016 |
| Denosumab 14 mg Q3M | -34.999 |
| Denosumab 30 mg Q3M | -52.656 |
| Denosumab 14 mg Q6M | -39.899 |
| Denosumab 60 mg Q6M | -51.494 |
| Denosumab 100 mg Q6M | -36.480 |
| Denosumab 210 mg Q6M | 7.067 |
| Alendronate 70 mg | -43.724 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.21 |
| Denosumab 6 mg Q3M | 1.82 |
| Denosumab 14 mg Q3M | 1.80 |
| Denosumab 30 mg Q3M | 2.74 |
| Denosumab 14 mg Q6M | 0.55 |
| Denosumab 60 mg Q6M | 2.51 |
| Denosumab 100 mg Q6M | 1.78 |
| Denosumab 210 mg Q6M | 2.08 |
| Alendronate 70 mg | 1.51 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.64 |
| Denosumab 6 mg Q3M | 2.59 |
| Denosumab 14 mg Q3M | 2.91 |
| Denosumab 30 mg Q3M | 4.44 |
| Denosumab 14 mg Q6M | 0.89 |
| Denosumab 60 mg Q6M | 2.57 |
| Denosumab 100 mg Q6M | 3.00 |
| Denosumab 210 mg Q6M | 2.75 |
| Alendronate 70 mg | 1.50 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.61 |
| Denosumab 6 mg Q3M | 3.14 |
| Denosumab 14 mg Q3M | 3.04 |
| Denosumab 30 mg Q3M | 2.34 |
| Denosumab 14 mg Q6M | 2.04 |
| Denosumab 60 mg Q6M | 2.80 |
| Denosumab 100 mg Q6M | 2.59 |
| Denosumab 210 mg Q6M | -0.29 |
| Alendronate 70 mg | 4.55 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 1.61 |
| Denosumab 6 mg Q3M | 1.90 |
| Denosumab 14 mg Q3M | 4.05 |
| Denosumab 30 mg Q3M | 8.85 |
| Denosumab 14 mg Q6M | 3.72 |
| Denosumab 60 mg Q6M | 4.92 |
| Denosumab 100 mg Q6M | 3.79 |
| Denosumab 210 mg Q6M | -0.75 |
| Alendronate 70 mg | 2.85 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.54 |
| Denosumab 6 mg Q3M | 3.68 |
| Denosumab 14 mg Q3M | 3.38 |
| Denosumab 30 mg Q3M | 3.76 |
| Denosumab 14 mg Q6M | 3.42 |
| Denosumab 60 mg Q6M | 3.43 |
| Denosumab 100 mg Q6M | 3.68 |
| Denosumab 210 mg Q6M | -0.29 |
| Alendronate 70 mg | 4.49 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 12 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.56 |
| Denosumab 6 mg Q3M | 2.89 |
| Denosumab 14 mg Q3M | 2.45 |
| Denosumab 30 mg Q3M | 3.32 |
| Denosumab 14 mg Q6M | 1.94 |
| Denosumab 60 mg Q6M | 3.56 |
| Denosumab 100 mg Q6M | 2.53 |
| Denosumab 210 mg Q6M | 2.33 |
| Alendronate 70 mg | 2.11 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.92 |
| Denosumab 6 mg Q3M | 4.04 |
| Denosumab 14 mg Q3M | 3.55 |
| Denosumab 30 mg Q3M | 5.03 |
| Denosumab 14 mg Q6M | 2.62 |
| Denosumab 60 mg Q6M | 4.96 |
| Denosumab 100 mg Q6M | 3.67 |
| Denosumab 210 mg Q6M | 4.18 |
| Alendronate 70 mg | 3.27 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -2.84 |
| Denosumab 6 mg Q3M | 4.79 |
| Denosumab 14 mg Q3M | 4.41 |
| Denosumab 30 mg Q3M | -1.23 |
| Denosumab 14 mg Q6M | 4.31 |
| Denosumab 60 mg Q6M | 5.83 |
| Denosumab 100 mg Q6M | 4.33 |
| Denosumab 210 mg Q6M | -1.43 |
| Alendronate 70 mg | 0.93 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.96 |
| Denosumab 6 mg Q3M | 5.01 |
| Denosumab 14 mg Q3M | 3.98 |
| Denosumab 30 mg Q3M | 2.37 |
| Denosumab 14 mg Q6M | 4.54 |
| Denosumab 60 mg Q6M | 6.34 |
| Denosumab 100 mg Q6M | 4.70 |
| Denosumab 210 mg Q6M | -2.67 |
| Alendronate 70 mg | 2.98 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -3.52 |
| Denosumab 6 mg Q3M | 5.45 |
| Denosumab 14 mg Q3M | 4.03 |
| Denosumab 30 mg Q3M | 3.86 |
| Denosumab 14 mg Q6M | 4.82 |
| Denosumab 60 mg Q6M | 6.06 |
| Denosumab 100 mg Q6M | 4.99 |
| Denosumab 210 mg Q6M | -1.37 |
| Alendronate 70 mg | 1.17 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and Month 12
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 24.300 |
| Denosumab 6 mg Q3M | -40.018 |
| Denosumab 14 mg Q3M | -54.688 |
| Denosumab 30 mg Q3M | -60.652 |
| Denosumab 14 mg Q6M | -2.027 |
| Denosumab 60 mg Q6M | -36.523 |
| Denosumab 100 mg Q6M | -51.256 |
| Denosumab 210 mg Q6M | -58.502 |
| Alendronate 70 mg | -45.409 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 24 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 14.422 |
| Denosumab 6 mg Q3M | -19.699 |
| Denosumab 14 mg Q3M | -37.691 |
| Denosumab 30 mg Q3M | -49.907 |
| Denosumab 14 mg Q6M | 2.134 |
| Denosumab 60 mg Q6M | -32.303 |
| Denosumab 100 mg Q6M | -37.001 |
| Denosumab 210 mg Q6M | -47.105 |
| Alendronate 70 mg | -44.482 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 36 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.508 |
| Denosumab 6 mg Q3M | -33.294 |
| Denosumab 14 mg Q3M | -47.752 |
| Denosumab 30 mg Q3M | 82.910 |
| Denosumab 14 mg Q6M | -44.301 |
| Denosumab 60 mg Q6M | -36.874 |
| Denosumab 100 mg Q6M | -27.174 |
| Denosumab 210 mg Q6M | 70.997 |
| Alendronate 70 mg | -15.627 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 42 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -18.102 |
| Denosumab 6 mg Q3M | -40.741 |
| Denosumab 14 mg Q3M | -40.043 |
| Denosumab 30 mg Q3M | -58.893 |
| Denosumab 14 mg Q6M | -47.188 |
| Denosumab 60 mg Q6M | -39.269 |
| Denosumab 100 mg Q6M | -46.674 |
| Denosumab 210 mg Q6M | 26.277 |
| Alendronate 70 mg | -33.102 |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100. (NCT00043186)
Timeframe: Baseline and 48 months
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -21.064 |
| Denosumab 6 mg Q3M | -23.311 |
| Denosumab 14 mg Q3M | -38.002 |
| Denosumab 30 mg Q3M | -50.864 |
| Denosumab 14 mg Q6M | -46.128 |
| Denosumab 60 mg Q6M | -40.375 |
| Denosumab 100 mg Q6M | -41.998 |
| Denosumab 210 mg Q6M | 7.884 |
| Alendronate 70 mg | -32.198 |
Percent Change in femoral neck BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -4.21 |
| Control | 0.04 |
Percent Change in lumbar spine BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 5.28 |
| Control | -1.48 |
Percent Change in peripheral heel BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 1.02 |
| Control | -1.99 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and FMP is calculated for each segment. We use iFMP (integrated FMP) as a measure of overall special frequency of the radiographic pattern. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 0.09 |
| Control | 1.04 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. We use sdRMS (standard deviation of the RMS across the segments) as a measure of the direction dependence (anisotropy) of the trabeculae in the bone image." (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 6.85 |
| Control | 1.08 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest in the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. The iRMS (integrated RMS) roughly corresponds to RMS averaged across all 24 angular sectors" (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.70 |
| Control | -0.53 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals and FMP is calculated for each segment. We use minFMP (minimum FMP) to represent the lowest value of FMP across the 24 angular sectors corresponding to the special frequency in the most washed-out direction. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.61 |
| Control | -0.18 |
The Percent Change in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) from Baseline to Month 24 is a description of the similarity of texture of the images at different magnifications. The Minkowski fractal dimension is calculated from the slope of the least -square fitted line relating log volume and log magnification. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -0.06 |
| Control | 0.12 |
The Percent Change in Radiographic Texture Analysis (RTA) spectral density coefficient beta (BETA) from Baseline to Month 24 is an analysis of spectral density vs. the spacial frequency on a log-log plot. BETA is the coefficient (slope) of this plot. Higher values of beta correspond to rougher (strong bone) and lower values to smoother, higher-frequency texture pattern (washed out bone). (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 3.09 |
| Control | 6.53 |
Percent Change in total hip BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.68 |
| Control | -0.77 |
40 reviews available for alendronate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of bisphosphonates on appendicular fracture repair in rodents.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; | 2022 |
[Risk assessment in patients undergoing osseous antiresorptive therapy in dentistry. An update].
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2013 |
Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Therapy, Combinat | 2015 |
Bone loss in patients with HIV infection.
Topics: Alendronate; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Bone Resorption | 2009 |
[New therapy using bisphosphonate for urolithiasis].
Topics: Alendronate; Animals; Bed Rest; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; C | 2011 |
Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism.
Topics: Alendronate; Animals; Bone Resorption; Evidence-Based Medicine; Humans; Hypercalcemia; Hyperparathyr | 2011 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Top | 2012 |
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density; Bone Density Con | 2013 |
New anabolic therapies in osteoporosis.
Topics: Alendronate; Bone and Bones; Bone Resorption; Drug Therapy, Combination; Female; Fluorides; Human Gr | 2002 |
Bisphosphonate mechanism of action.
Topics: Alendronate; Animals; Bone Resorption; Cholesterol; Cytoskeleton; Diphosphonates; Diterpenes; Humans | 2002 |
[Pharmacological and clinical properties of alendronate sodium hydrate].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clinical Trials as Topic; Depression, Chemical; | 2002 |
Preclinical evidence of normal bone with alendronate.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Density; Bone Resorption; Drug Evaluatio | 1999 |
[Cross-linked N-telopeptides of type I collagen(NTX)].
Topics: Alendronate; Biomarkers; Bone Resorption; Cathepsin K; Cathepsins; Collagen; Collagen Type I; Enzyme | 2004 |
[Serum beta-CTx(beta-CrossLaps)].
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Fractures, Bone; | 2004 |
[Treatment of osteoporosis with alendronate].
Topics: Alendronate; Apoptosis; Bone Density; Bone Resorption; Clinical Trials as Topic; Fractures, Bone; Hu | 2004 |
Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
Topics: Alendronate; Bone Density; Bone Resorption; Drug Interactions; Female; Humans; Osteoporosis; Parathy | 2004 |
Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Diphosphonates; Estrogen Re | 2003 |
Postmenopausal osteoporosis and alendronate.
Topics: Aged; Alendronate; Bone Density; Bone Resorption; Female; Femur Neck; Fractures, Bone; Humans; Lumba | 2004 |
[Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Drug Therapy, Combination; Humans; Insulin Rece | 2005 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C | 2005 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu | 2005 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; | 2005 |
Combination therapy for osteoporosis: considerations and controversy.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combin | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; | 2006 |
Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph | 2007 |
Interaction between IGF-1, inflammation, and neuropathy in the pathogenesis of acute charcot neuroarthropathy: lessons from alendronate therapy and future perspectives of medical therapy.
Topics: Acute Disease; Alendronate; Arthropathy, Neurogenic; Bone Density Conservation Agents; Bone Resorpti | 2008 |
Bisphosphonates in the treatment of metabolic bone diseases.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Humans; Hyp | 1993 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteo | 1997 |
Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Female; Humans; Osteoporosis, Postmenop | 1997 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C | 1997 |
How do bone resorption inhibitors increase bone mineral density?
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Bone Resorption; Diphosphonates; Humans | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Weekly administration of alendronate: rationale and plan for clinical assessment.
Topics: Alendronate; Animals; Bone Remodeling; Bone Resorption; Dogs; Humans | 2000 |
Bisphosphonates: an overview with special reference to alendronate.
Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho | 2001 |
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
Topics: Alendronate; Bone Density; Bone Resorption; Female; Fractures, Spontaneous; Humans; Logistic Models; | 2002 |
[Alendronate in the treatment of osteoporosis].
Topics: Alendronate; Bone Density; Bone Resorption; Clinical Trials as Topic; Femoral Neck Fractures; Fractu | 2002 |
Treatment of male osteoporosis: recent advances with alendronate.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Resorption; Calcium; Female; Fractures, Bone; Humans; H | 2002 |
82 trials available for alendronate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; B | 2020 |
The effects of alendronate on the suppression of bone resorption and the promotion of cartilage formation in the human mosaicplasty donor site: A randomized, double-blind, placebo-controlled prospective study.
Topics: Alendronate; Animals; Bone Resorption; Cartilage, Articular; Chondrogenesis; Female; Humans; Knee Jo | 2022 |
Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; | 2017 |
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Topics: Adult; Aged; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density; | 2014 |
Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cath | 2014 |
Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Bone Resorp | 2013 |
A negative feedback model for a mechanism based description of longitudinal observations. Application for bone turnover biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone | 2013 |
Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Topics: Aged; Alendronate; Area Under Curve; Bone and Bones; Bone Density; Bone Resorption; Cathepsin K; Col | 2015 |
Effects of long-term alendronate treatment on bone mineralisation, resorption parameters and biomechanics of single human vertebral trabeculae.
Topics: Aged; Aged, 80 and over; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Bon | 2014 |
Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Density Conservation Agents; | 2015 |
Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density | 2015 |
Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cholecalciferol | 2016 |
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bo | 2008 |
The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial.
Topics: Absorbable Implants; Adult; Alendronate; Alveolar Bone Loss; Alveolar Process; Biocompatible Materia | 2008 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents | 2009 |
Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Knee; Bone De | 2009 |
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; | 2010 |
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorptio | 2010 |
Alendronate reduces osteoclast precursors in osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Cells, Cultured; Cyto | 2010 |
Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; B | 2010 |
Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; | 2011 |
Effect of methylprednisolone pulse therapy with and without alendronate on biochemical markers of bone turnover in patients with Graves' ophthalmopathy.
Topics: Absorptiometry, Photon; Adult; Alendronate; Anti-Inflammatory Agents; Biomarkers; Bone Density; Bone | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dip | 2012 |
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; | 2013 |
A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Topics: Aged; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remod | 2013 |
Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Body Composition; Bone Density; Bone Density | 2013 |
Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases.
Topics: Adolescent; Alendronate; Anthropometry; Biomarkers; Bone Density; Bone Resorption; Child; Child, Pre | 2002 |
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Body Height; Bone and | 2002 |
Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Resor | 2002 |
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Topics: Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Double-Blind Method; Female; Gastr | 2002 |
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Resorption; Co | 2002 |
Alendronate in the prevention of bone loss after a fracture of the lower leg.
Topics: Adult; Alendronate; Bone Resorption; Double-Blind Method; Female; Humans; Male; Middle Aged; Prospec | 2002 |
The effects of alendronate on bone turnover and bone quality.
Topics: Alendronate; Bone and Bones; Bone Remodeling; Bone Resorption; Calcium Carbonate; Double-Blind Metho | 1999 |
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Estrogen Replacement Therapy; Female; H | 2003 |
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium C | 2003 |
Efficacy of alendronate in adults with cystic fibrosis with low bone density.
Topics: Administration, Oral; Adult; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Cysti | 2004 |
Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
Topics: Adult; Alendronate; Azathioprine; Bone Density; Bone Resorption; Calcitriol; Calcium Channel Agonist | 2003 |
Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Resorption; Disabi | 2003 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Double-Blind Method; F | 2004 |
Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Topics: Adult; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Case-Control Studies; | 2004 |
Prevention of bone loss in paraplegics over 2 years with alendronate.
Topics: Adult; Alendronate; Amino Acids; Bone Density; Bone Remodeling; Bone Resorption; Calcium; Creatinine | 2004 |
Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Back Pain; Biomarkers; Bone Density; B | 2004 |
Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Alendronate; Asthma; Bone and Bones; Bone | 2005 |
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Topics: Absorptiometry, Photon; Administration, Inhalation; Administration, Intranasal; Alendronate; Alkalin | 2005 |
Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
Topics: Administration, Oral; Adolescent; Alendronate; Arthritis, Juvenile; Body Height; Bone Density; Bone | 2005 |
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Do | 2004 |
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorp | 2005 |
Trabecular bone microarchitecture after alendronate treatment of osteoporotic women.
Topics: Aged; Aged, 80 and over; Alendronate; Biopsy; Bone Density; Bone Resorption; Electron Probe Microana | 2005 |
Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial.
Topics: Acute Disease; Alendronate; Arthropathy, Neurogenic; Bone Resorption; Diabetic Neuropathies; Disabil | 2005 |
Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bon | 2005 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bo | 2006 |
Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
Topics: Adult; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone | 2006 |
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Calcium; Drug Ther | 2006 |
Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Arthroplasty, Replacement, Hip; Bone Density Conserv | 2006 |
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorp | 2007 |
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Biomarkers; Bone Density; Bone De | 2007 |
Alendronate inhibits periprosthetic bone loss around uncemented femoral components.
Topics: Aged; Alendronate; Amino Acids; Bone Cements; Bone Density; Bone Density Conservation Agents; Bone R | 2007 |
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Densi | 2007 |
Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
Topics: Alendronate; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcium; Diphosphonates; Enzyme | 1994 |
Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women.
Topics: Alendronate; Bone Density; Bone Development; Bone Resorption; Diphosphonates; Dose-Response Relation | 1993 |
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Resorption; Double- | 1996 |
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.
Topics: Adult; Alendronate; Anthropometry; Bone Density; Bone Resorption; Double-Blind Method; Drug Administ | 1998 |
Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.
Topics: Aged; Alendronate; Biomarkers; Bone and Bones; Bone Resorption; Circadian Rhythm; Collagen; Collagen | 1998 |
Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Cal | 1998 |
Effect of antiresorptive therapy on day-to-day variation of urinary free deoxypyridinoline excretion.
Topics: Aged; Alendronate; Amino Acids; Biomarkers; Bone Resorption; Enzyme-Linked Immunosorbent Assay; Fema | 1998 |
Monitoring alendronate therapy for osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Remodeling; Bon | 1999 |
Treatment of Paget's disease of bone with alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Resorption; Etidronic Acid; | 1999 |
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphona | 1999 |
Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
Topics: Alendronate; Alkaline Phosphatase; Asia; Biomarkers; Bone Density; Bone Resorption; Collagen; Collag | 1999 |
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Biomarkers; | 1999 |
Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate.
Topics: Adult; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; beta 2-Microglobulin; Bone and Bone | 1999 |
Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Resorption; Female; Humans; Incidence; Lumb | 1999 |
The effect of alendronate on bone mass after distal forearm fracture.
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Reso | 2000 |
Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Double-Blin | 2000 |
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Topics: Adult; Aged; Alendronate; Arthrography; Bone Density; Bone Resorption; Double-Blind Method; Female; | 2001 |
Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Biomarkers; Bone Resorption; Case-Control Studies | 2001 |
[Effect of alendronate therapy on bone turnover--results of a multicenter study].
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Calcium; Collagen; Collagen | 2000 |
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.
Topics: Alendronate; Analysis of Variance; Bone Resorption; Cartilage; Collagen Type I; Collagen Type II; Di | 2002 |
Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Doub | 1992 |
Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
Topics: Aged; Alendronate; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Dose-Response Relations | 1992 |
Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Resorption; Clinical Trials as Topic; Dipho | 1990 |
249 other studies available for alendronate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
Topics: Animals; Bone Resorption; Diphosphonates; Fatty Acids; Humans; Inhibitory Concentration 50; Parasiti | 2001 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitor | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphos | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques | 2002 |
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium | 2005 |
Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Cell Proliferati | 2008 |
Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cathepsin K | 2017 |
Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation.
Topics: Alkanes; Animals; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans | 2020 |
Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Female; Follow-Up Studies; Humans; Immunoglobul | 2022 |
Effects of Alendronate and Dexamethasone on Osteoclast Gene Expression and Bone Resorption in Mouse Marrow Cultures.
Topics: Alendronate; Animals; Bone Marrow; Bone Resorption; Cattle; Cell Survival; Cells, Cultured; Dexameth | 2022 |
Effect of
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bone Resorption; Cell Differentiation; Estradiol; Es | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Osteophilic and Dual-Regulated Alendronate-Gene Lipoplexes for Reversing Bone Loss.
Topics: Alendronate; Antagomirs; Bone and Bones; Bone Resorption; Humans; MicroRNAs | 2023 |
An osteoporosis bone defect regeneration strategy via three-dimension short fibers loaded with alendronate modified hydroxyapatite.
Topics: Alendronate; Bone Regeneration; Bone Resorption; Durapatite; Humans; Osteogenesis; Osteoporosis; Pol | 2024 |
Alendronate inhibits osteocyte apoptosis and inflammation via IL-6, inhibiting bone resorption in periapical lesions of ovariectomized rats.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Female; Humans; | 2020 |
Local application of alendronate controls bone formation and β-tricalcium phosphate resorption induced by recombinant human bone morphogenetic protein-2.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Resorptio | 2020 |
Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Glucocorticoids; Humans; Osteoporosis; Rats; | 2020 |
Functional Block of Interleukin-6 Reduces a Bone Pain Marker but Not Bone Loss in Hindlimb-Unloaded Mice.
Topics: Alendronate; Animals; Behavior, Animal; Biomarkers; Bone and Bones; Bone Resorption; Ganglia, Spinal | 2020 |
Combined Pharmacotherapy with Alendronate and Desferoxamine Regulate the Bone Resorption and Bone Regeneration for Preventing Glucocorticoids-Induced Osteonecrosis of the Femoral Head.
Topics: Alendronate; Animals; beta Catenin; Bone Regeneration; Bone Resorption; Deferoxamine; Drug Therapy, | 2020 |
Bisphosphonates impair the onset of bone formation at remodeling sites.
Topics: Alendronate; Bone Remodeling; Bone Resorption; Diphosphonates; Humans; Osteoclasts; Osteogenesis | 2021 |
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Model | 2021 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Cons | 2017 |
Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Density Conservation | 2017 |
High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome.
Topics: Adult; Alendronate; Animals; Base Sequence; Bone Diseases, Metabolic; Bone Marrow Cells; Bone Remode | 2018 |
Tracking the Progression of Osteolytic and Osteosclerotic Lesions in Mice Using Serial In Vivo μCT: Applications to the Assessment of Bisphosphonate Treatment Efficacy.
Topics: Alendronate; Animals; Bone Resorption; Cell Line, Tumor; Diphosphonates; Disease Progression; Female | 2018 |
Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.
Topics: Alendronate; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Bone Resorptio | 2018 |
Inhibition of bone resorption by bisphosphonates interferes with orthodontically induced midpalatal suture expansion in mice.
Topics: Alendronate; Animals; Bone Remodeling; Bone Resorption; Cranial Sutures; Diphosphonates; Immunohisto | 2018 |
Healing of fractures in osteoporotic bones in mice treated with bisphosphonates - A transcriptome analysis.
Topics: Alendronate; Animals; Biomarkers; Bone Resorption; Cluster Analysis; Diphosphonates; Disease Models, | 2018 |
The Beneficial Effect of Proanthocyanidins and Icariin on Biochemical Markers of Bone Turnover in Rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2018 |
Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; China; Female; H | 2019 |
MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice.
Topics: Alendronate; AMP-Activated Protein Kinases; Animals; Bone Density Conservation Agents; Bone Resorpti | 2019 |
Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone Densit | 2013 |
Prefabrication of vascularized bone allograft in a recipient rat using a flow-through vascular pedicle, bone morphogenetic protein, and bisphosphonate.
Topics: Alendronate; Animals; Arteries; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone | 2013 |
Reduced RANKL expression impedes osteoclast activation and tooth eruption in alendronate-treated rats.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Diff | 2013 |
Reversing bone loss by directing mesenchymal stem cells to bone.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Cell Differentiation; Cell Movement; D | 2013 |
Immunolocalization of Smad-4 in developing molar roots of alendronate-treated rats.
Topics: Alendronate; Animals; Bone Morphogenetic Proteins; Bone Resorption; Cell Differentiation; Cementogen | 2013 |
Crystalline calcium alendronate obtained by octacalcium phosphate digestion: a new chance for local treatment of bone loss diseases?
Topics: Alendronate; Bone Resorption; Calcium; Calcium Phosphates; Cell Differentiation; Cell Proliferation; | 2013 |
Local administration of alendronate reduced peri-tunnel bone loss and promoted graft-bone tunnel healing with minimal systemic effect on bone in contralateral knee.
Topics: Alendronate; Animals; Anterior Cruciate Ligament Reconstruction; Biomechanical Phenomena; Bone Densi | 2013 |
Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Topics: Absorptiometry, Photon; Adaptor Proteins, Signal Transducing; Alendronate; Animals; Bone and Bones; | 2013 |
The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits.
Topics: Alendronate; Animals; Biphenyl Compounds; Bone and Bones; Bone Density Conservation Agents; Bone Rem | 2014 |
Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Eye Disea | 2014 |
Effect of bisphosphonates on the rapidly growing male murine skeleton.
Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Res | 2014 |
Prevention of the surface resorption of bone grafts by topical application of bisphosphonate on different carrier materials.
Topics: Administration, Topical; Alendronate; Alveolar Ridge Augmentation; Animals; Bone Resorption; Cattle; | 2014 |
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; C | 2014 |
The role of muscle loading on bone (Re)modeling at the developing enthesis.
Topics: Alendronate; Animals; Animals, Newborn; Anthraquinones; Bone Density Conservation Agents; Bone Resor | 2014 |
Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Bone Resorption; Cartilage, Articular; Disease Pr | 2014 |
Osteoarthritis: alendronate treatment improves pathology in animal model of OA by blocking osteoclastic bone resorption.
Topics: Alendronate; Animals; Bone Resorption; Disease Progression; Male; Osteoarthritis; Osteoclasts | 2014 |
Re: Persistence of 1,25D-induced hypercalciuria in alendronate treated genetic hypercalciuric stone-forming rats fed a low calcium diet.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietar | 2014 |
The standardized BHH10 extract, a combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, reverses bone mass and metabolism in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Astragalus propinquus; Body Weight; Bone Density; Bone Resorption; Cinnamomum | 2015 |
μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Drug Therap | 2015 |
Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diabetes Mell | 2015 |
Anti-RANKL treatment improves screw fixation in cancellous bone in rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Fracture He | 2015 |
Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Cathepsin K; Female; Osteogenesis; Ovariectomy; | 2016 |
Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.
Topics: Alendronate; Animals; Anterior Cruciate Ligament Injuries; Bone Density Conservation Agents; Bone Re | 2015 |
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen; Dis | 2015 |
Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Cells, Cultured; | 2015 |
Bone metabolism and renal stone risk during International Space Station missions.
Topics: Adult; Alendronate; Astronauts; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation | 2015 |
Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate.
Topics: Alendronate; Animals; Biphenyl Compounds; Bone Resorption; Female; Gene Expression Regulation; Macac | 2016 |
Self-assembling bisphosphonates into nanofibers to enhance their inhibitory capacity on bone resorption.
Topics: Alendronate; Bone Resorption; Cells, Cultured; Diphosphonates; Humans; Hydrogels; Nanofibers; Osteoc | 2016 |
Earlier effect of alendronate in mouse metaphyseal versus diaphyseal bone healing.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Bone Screws; Cancellous Bon | 2017 |
Aqueous extract of pomegranate seed attenuates glucocorticoid-induced bone loss and hypercalciuria in mice: A comparative study with alendronate.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Duodenum; Glucocorticoids; Hypercalciuria; Kidney; L | 2016 |
Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Topics: Alendronate; Animals; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Caspases; Cell | 2017 |
Nanocomposite scaffolds with tunable mechanical and degradation capabilities: co-delivery of bioactive agents for bone tissue engineering.
Topics: Alendronate; Alginates; Animals; Biocompatible Materials; Bone and Bones; Bone Marrow Cells; Bone Re | 2016 |
Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Disease Progression; Drug Eva | 2017 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Topics: Alendronate; Animals; Biological Assay; Biological Transport; Biomarkers; Bone and Bones; Bone Marro | 2008 |
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
Topics: Alendronate; Animals; Apoptosis; Bone Density; Bone Resorption; Cell Differentiation; Cells, Culture | 2008 |
Bisphosphonates in children with hypercalciuria and reduced bone mineral density.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; C | 2008 |
Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
Topics: Alendronate; Animals; Animals, Newborn; Benzoates; Biphenyl Compounds; Bone Marrow Cells; Bone Resor | 2009 |
Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Resorption; Dipeptides | 2008 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Drug Administration Schedule; | 2009 |
Effect of eicosapentaenoic acid on bone changes due to methylprednisolone in rats.
Topics: Alendronate; Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density Conservation Agents; Bon | 2009 |
The efficacy of alendronate in wheelchair-bound patients: a 1-year prospective study.
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone | 2009 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Dise | 2009 |
Experimental results of combining bisphosphonates with allograft in a rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Bone Transpla | 2009 |
Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Equipment D | 2009 |
Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation.
Topics: Alendronate; Animals; Bone Resorption; Cell Line; Chemokine CCL2; Down-Regulation; Lipid A; Lipopept | 2009 |
Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Bone Resorption; Collagen Type I; Cross-Secti | 2009 |
Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
Topics: Alendronate; Animals; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Bon | 2010 |
A woman with progressive thinning of the skull.
Topics: Aged; Alendronate; Bone Density; Bone Resorption; Disease Progression; Female; Humans; Parietal Bone | 2009 |
Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys.
Topics: Alendronate; Animals; Azepines; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone | 2009 |
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggreg | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Topics: Alendronate; Animals; Biological Availability; Bone and Bones; Bone Density; Bone Density Conservati | 2010 |
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female; | 2010 |
Effect of alendronate on alveolar bone resorption and angiogenesis in rats with experimental periapical lesions.
Topics: Acid Phosphatase; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Density Conservat | 2010 |
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone an | 2010 |
In situ fabrication of alendronate-loaded calcium phosphate microspheres: controlled release for inhibition of osteoclastogenesis.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphat | 2010 |
[Comparison of effects of Wujia Bugu decoction) and alendronate sodium on protection the bone loss of hindlimb unloaded rats].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Disease Models, Animal; Drugs, Chinese Herbal; | 2010 |
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits.
Topics: Alendronate; Animals; Biphenyl Compounds; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bo | 2011 |
Effects of alendronate on bone healing after tooth extraction in rats.
Topics: Alendronate; Alveolar Process; Animals; Blood Vessels; Bone Density; Bone Density Conservation Agent | 2010 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; H | 2010 |
Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms | 2011 |
Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Density Conservation Agents; Bone Plates; Bone Resorpti | 2011 |
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.
Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; | 2010 |
Bone morphology in response to alendronate as seen by high-resolution computed tomography: Through a glass darkly.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Female | 2010 |
The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density; Bone Density Co | 2011 |
Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone | 2011 |
Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Marrow; Bone Resorption; CD4-Positive T-Lymphoc | 2011 |
[Alendronate and resorptive hypercalciuria].
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; C | 2011 |
Efficacy of serotonin inhibition in mouse models of bone loss.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Dose-Response | 2011 |
Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation.
Topics: Alendronate; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; C | 2011 |
Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservati | 2011 |
Polarized osteoclasts put marks of tartrate-resistant acid phosphatase on dentin slices--a simple method for identifying polarized osteoclasts.
Topics: Acid Phosphatase; Actins; Alendronate; Animals; Bone Resorption; Calcitonin; Cathepsin K; Cell Polar | 2011 |
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid | 2012 |
Impregnation of bone chips with alendronate and cefazolin, combined with demineralized bone matrix: a bone chamber study in goats.
Topics: Alendronate; Animals; Anti-Bacterial Agents; Bone Demineralization Technique; Bone Density Conservat | 2012 |
A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: a histologic and histomorphometric study in a rat calvarial defect model.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; Bone Resorption; Bone | 2012 |
Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Topics: Acid Phosphatase; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bisphosphonate-A | 2013 |
Nonhealing gastric ulcer caused by chronic alendronate administration.
Topics: Abdominal Pain; Aged; Alendronate; Anti-Ulcer Agents; Bone Resorption; Drug Administration Schedule; | 2002 |
Skeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot study.
Topics: Adult; Aged; Alendronate; Bone Remodeling; Bone Resorption; Female; Fractures, Bone; Humans; Isotope | 2002 |
New bone drug benefit. Less skeletal lead released.
Topics: Adult; Aged; Alendronate; Bone Resorption; Female; Humans; Isotopes; Lead; Male; Middle Aged; Osteop | 2002 |
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Dose-Response Relationship, | 2002 |
Alendronate interacts with the inhibitory effect of 1,25(OH)2D3 on parathyroid hormone-related protein expression in human osteoblastic cells.
Topics: Alendronate; Bone Resorption; Calcitriol; Calcium Signaling; Cells, Cultured; Dose-Response Relation | 2003 |
Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients.
Topics: Acro-Osteolysis; Adult; Alendronate; Bone Density; Bone Diseases, Developmental; Bone Resorption; Fe | 2003 |
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Topics: Adenosine Triphosphate; Alendronate; Animals; Apoptosis; Blotting, Western; Bone Resorption; Cell Li | 2003 |
The influence of alendronate on bone formation and resorption in a rat ectopic bone development model.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Bon | 2003 |
A rat model for testing pharmacologic treatments of pressure-related bone loss.
Topics: Alendronate; Animals; Antirheumatic Agents; Bone Plates; Bone Resorption; Disease Models, Animal; Dr | 2003 |
New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Drug Administration Sc | 2003 |
Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Chromatogra | 2003 |
A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
Topics: Alendronate; Bone Resorption; Diphosphonates; Heterocyclic Compounds; Models, Molecular; Pamidronate | 2003 |
Osteoporosis options. Choose medication based on age, health, and family history.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Estrogens; Humans; Osteogenesis; Osteopo | 2003 |
Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Anti-Bacterial | 2003 |
Increased bone resorption and failure to respond to antiresorptive therapy in progressive dystrophic calcification.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcino | 2003 |
M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Topics: Acid Phosphatase; Actins; Adaptor Proteins, Signal Transducing; Alendronate; Alkyl and Aryl Transfer | 2003 |
A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Resorption; Chi-Square Distribution | 2003 |
Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Topics: Acid Phosphatase; Aged; Alendronate; Biomarkers; Bone Resorption; Calcium; Diet; Female; Humans; Imm | 2004 |
Bone loss after cardiac transplantation.
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Collagen; Collagen Type I; Fract | 2004 |
Effect of alendronate on osteoclast differentiation and bone volume in transplanted bone.
Topics: Alendronate; Animals; Bone Resorption; Bone Transplantation; Cell Differentiation; Histocytochemistr | 2004 |
Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis.
Topics: Alendronate; Animals; Arthritis, Experimental; Bone Density; Bone Resorption; Diphosphonates; Etidro | 2004 |
Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis.
Topics: Alendronate; Bone Resorption; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Meta- | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Resorption; Calcitriol; Drug Therapy, Combination; Estrogens; Humans; Organ Transp | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Resorption; Calcitriol; Calcium; Cyclosporine; Drug Therapy, Combination; Heart Tr | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Creatinine; Cyclosporine; Female; Heart Tran | 2004 |
Bone anabolic agents: the unanswered queries.
Topics: Alendronate; Anabolic Agents; Animals; Bone Resorption; Clinical Trials as Topic; Female; Humans; Ma | 2004 |
The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis.
Topics: Aged; Alendronate; Arthrography; Bone Resorption; Case-Control Studies; Cross-Sectional Studies; Est | 2004 |
Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study.
Topics: Adolescent; Adult; Aged; Alendronate; Bone Resorption; Disability Evaluation; Female; Femur Head Nec | 2005 |
Severely suppressed bone turnover: a potential complication of alendronate therapy.
Topics: Aged; Alendronate; Biopsy; Bone Density; Bone Resorption; Female; Fracture Healing; Fractures, Bone; | 2005 |
Alendronate inhibits bone resorption at the bone-screw interface.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Bone Screws; Cathepsin K; Cathepsins; Disea | 2005 |
Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Remodeling; Bone Resorption; Bone Transplantatio | 2004 |
Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Resorptio | 2005 |
[Effects of L-threonate on bone resorption by osteoclasts in vitro].
Topics: Alendronate; Animals; Bone Resorption; Butyrates; Cells, Cultured; Collagen; Collagen Type I; Estrad | 2005 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diph | 2005 |
Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antimetabolites; Bone and Bones; Bone Resorption; Cl | 2005 |
[Optimal osteoporosis strategy?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Drug Therapy, Combination; | 2005 |
Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Bone Resorption; Calcitonin; Calcium; Cell Line, Tumor | 2005 |
[To increase bone density faster and stronger].
Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter | 2005 |
Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Remodel | 2005 |
Effect of alendronate administration on bone mineral density and bone strength in castrated rats.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Body Weight; | 2005 |
Modulation of bone turnover by alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs.
Topics: Absorptiometry, Photon; Adjuvants, Immunologic; Alendronate; Animals; Body Weight; Bone and Bones; B | 2005 |
Effect of Korean oriental medicine extract on bone mass as compared with alendronate in ovariectomized rats.
Topics: Acid Phosphatase; Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Rem | 2005 |
Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Topics: Alendronate; Animals; Binding, Competitive; Bone and Bones; Bone Density Conservation Agents; Bone R | 2006 |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Morphogenetic Proteins; Bone Resorption; Cattle; Ch | 2005 |
Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats.
Topics: Alendronate; Alveolar Bone Loss; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bone Dens | 2005 |
Role of the osteoclast in cranial suture waveform patterning.
Topics: Acid Phosphatase; Age Factors; Aging; Alendronate; Animals; Animals, Newborn; Bone Density Conservat | 2006 |
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorpti | 2006 |
[Very old patients with osteoporosis should be treated with alendronate].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; B | 2006 |
Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density Conservation Ag | 2006 |
Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservati | 2007 |
Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
Topics: Alendronate; Amino Acids; Animals; Bone Density Conservation Agents; Bone Resorption; Bone Transplan | 2007 |
Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria.
Topics: Adult; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; | 2007 |
Systemic alendronate treatment improves fixation of press-fit implants: a canine study using nonloaded implants.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Dogs; Osseointegration; Ost | 2007 |
Summaries for patients. Preventing bone loss in men with prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Biomarkers; Bone Density; Bone De | 2007 |
Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorptio | 2007 |
Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function.
Topics: Actins; Alendronate; Animals; Bone Density Conservation Agents; Bone Marrow Cells; Bone Resorption; | 2007 |
Re: 'A single zoleledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density' by Saag et al.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density; Bone Resorption; Diphosphonates; Humans | 2007 |
[Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorptio | 2007 |
Alendronate treatment in the revision setting, with and without controlled implant motion: an experimental study in dogs.
Topics: Alendronate; Animals; Arthroplasty, Replacement; Bone Density Conservation Agents; Bone Resorption; | 2007 |
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Line, Tumor; Cell Surv | 2008 |
Latent hypoparathyroidism in an osteoporotic patient with multiple endocrinopathies and secondary hemochromatosis due to multiple blood transfusions, unmasked by alendronate and glucocorticoid at adrenal crisis.
Topics: Adrenal Glands; Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Diab | 2008 |
Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study.
Topics: Alendronate; Animals; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone | 2008 |
Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK).
Topics: Adult; Alendronate; Animals; Bone Resorption; Calcium; Diphosphonates; Female; Granulocyte Colony-St | 1994 |
Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bon | 1995 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.
Topics: Alendronate; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcific | 1994 |
Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
Topics: Aged; Alendronate; Biomarkers; Bone Resorption; Diphosphonates; Female; Humans; Hydroxylysine; Hydro | 1994 |
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosp | 1994 |
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Diphosphonates; Di | 1993 |
Alendronate: some remaining paradoxes.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Diphosphonates; Female; Humans; Osteoporosis | 1993 |
Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Development; Bone | 1993 |
Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo.
Topics: Alendronate; Animals; Bone and Bones; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Count; D | 1993 |
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; | 1993 |
Inhibition of antigen-presenting cell function by alendronate in vitro.
Topics: Alendronate; Bone Resorption; Cell Division; Cell Survival; Cells, Cultured; Diphosphonates; Dose-Re | 1995 |
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate.
Topics: Alendronate; Amino Acid Sequence; Animals; Arsenicals; Bone Marrow Cells; Bone Resorption; Cloning, | 1996 |
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Cell Line; Culture Media, Conditioned; Diph | 1996 |
Effects of alendronate on plasma calcium levels, urinary calcium excretion, and bone resorption markers in normal rats: comparison with elcatonin, synthetic eel calcitonin.
Topics: Alendronate; Amino Acids; Animals; Bone Resorption; Calcitonin; Calcium; Circadian Rhythm; Diphospho | 1996 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Di | 1996 |
[Reduction of the Nordin index after therapy with oral alendronate in patients with postmenopausal osteoporosis].
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density; Bone Resorption; Diphosphonates; Femal | 1995 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Mo | 1996 |
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cel | 1996 |
The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
Topics: Alendronate; Animals; Binding, Competitive; Bone Resorption; Cell Membrane Permeability; Chickens; D | 1996 |
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antigens; Bone Marrow; Bone Marrow Cells; Bone Resorpt | 1997 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
Alendronate prevents cyclosporin A-induced osteopenia in the rat.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Body Weight; Bone Diseases, Metabo | 1997 |
Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone.
Topics: Acid Phosphatase; Alendronate; Amino Acids; Animals; Anti-Inflammatory Agents; Biomarkers; Bone Marr | 1997 |
Alendronate: preclinical studies.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Bone Resorption; Disease Models, Animal; Female | 1997 |
The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model.
Topics: Alendronate; Animals; Awards and Prizes; Bone Resorption; Dinoprostone; Dogs; Evaluation Studies as | 1997 |
Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Diseases; | 1997 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; E | 1998 |
[Role of bones in the physiopathology of idiopathic hypercalciuria: effect of amino-bisphosphonate alendronate].
Topics: Alendronate; Bone and Bones; Bone Density; Bone Resorption; Calcium; Cytokines; Humans; Hydroxyproli | 1997 |
Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption.
Topics: Alendronate; Amino Acids; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Estroge | 1998 |
Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Betaine; Bone and Bones; Bone Resorption; Calcinosis | 1998 |
Alendronate/interleukin-1beta cotreatment increases interleukin-6 in bone and UMR-106 cells: dose dependence and relationship to the antiresorptive effect of alendronate.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Cell Line; Cyclooxygenase Inhibitors; Dose-Re | 1998 |
Osteoblastic responses to TGF-beta during bone remodeling.
Topics: Alendronate; Animals; Bone Remodeling; Bone Resorption; Cell Count; Cell Differentiation; Femur; Gen | 1998 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle | 1998 |
Pre-emptive bone strikes in prevention of osteoporosis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Resorption; Estradiol Congeners; Female; Humans; Ost | 1998 |
Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
Topics: Alendronate; Animals; Bone Resorption; Diphosphonates; Dogs; Esophagus; Etidronic Acid; Mucous Membr | 1998 |
Human osteoclast formation and activity in vitro: effects of alendronate.
Topics: Aged; Alendronate; Analysis of Variance; Bone and Bones; Bone Resorption; Cell Differentiation; Cocu | 1998 |
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; Culture | 1998 |
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Topics: Alendronate; Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Cholesterol; Clodronic | 1999 |
Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium Oxalate; Calcium Phosphates; Calcium, Dietar | 1999 |
Alendronate did not inhibit instability-induced bone resorption. A study in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Disease Models, Animal; Drug Evaluation, Preclin | 1999 |
Short-term effects of bisphosphonates on the biomechanical properties of canine bone.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Biomechanical Phenomena; Bone and Bones; Bone | 1999 |
Clinical usefulness of biochemical resorption markers in osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Resorption; Female; Humans; Immunoenzyme Tech | 1999 |
Disposition of alendronate following local delivery in a rat jaw.
Topics: Absorption; Administration, Topical; Alendronate; Animals; Bone Resorption; Mandible; Osteotomy; Rat | 1999 |
Biochemical bone markers.
Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Fem | 1999 |
Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption | 1999 |
Frequency of bone densitometry for osteoporosis?
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitonin; Estrogen | 1999 |
Collagen crosslinked N-telopeptides as markers for evaluating particulate osteolysis: a preliminary study.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Resorption; Collagen; Creatinine; Female; Humans; Male; M | 2000 |
Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Resorption; Circadian Rhythm; Clinical Trial | 2000 |
The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase.
Topics: Alendronate; Alkyl and Aryl Transferases; Amino Acid Sequence; Animals; Base Sequence; Bone Resorpti | 2000 |
Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Bone Resorption; Female; Humans; Middle Aged; Osteopor | 2000 |
Development and evaluation of C-telopeptide enzyme-linked immunoassay for measurement of bone resorption in mouse serum.
Topics: Alendronate; Amino Acid Sequence; Animals; Bone Resorption; Calcium; Collagen; Collagen Type I; Enzy | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton | 2000 |
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitor | 2000 |
Alendronate stimulates collagenase 3 expression in osteoblasts by posttranscriptional mechanisms.
Topics: Alendronate; Animals; Blotting, Northern; Blotting, Western; Bone Remodeling; Bone Resorption; Cells | 2000 |
Once-a-week alendronate (Fosamax).
Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials a | 2001 |
Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression.
Topics: Alendronate; Antibodies, Monoclonal; Apoptosis; Bone Resorption; Cell Adhesion; Cell Nucleus; Chroma | 2000 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diph | 2001 |
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Topics: Adenosine Triphosphate; Alendronate; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Ap | 2001 |
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Topics: Actins; Alendronate; Animals; Apoptosis; Bone Resorption; Cytoskeleton; Etidronic Acid; Mice; Osteoc | 2001 |
A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Amino Acid Sequence; Animals; Antibodies, M | 2001 |
[The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Resorption; Calcium; Disease Models, Anim | 2001 |
Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcium; Carcinoma 256, Walker; Drug Administ | 2002 |
Alendronate does not inhibit early bone apposition to hydroxyapatite-coated total joint implants: a preliminary study.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Remodeling; Bone Resorption; Dogs; Durapa | 2002 |
Effects of alendronate on particle-induced osteolysis in a rat model.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Injections, Intra-Art | 2002 |
Development of a synthetic peptide-based tartrate-resistant acid phosphatase radioimmunoassay for the measurement of bone resorption in rat serum.
Topics: Acid Phosphatase; Alendronate; Animals; Antibodies; Biomarkers; Bone Density; Bone Resorption; Colla | 2002 |
Alendronate disturbs vesicular trafficking in osteoclasts.
Topics: Acid Phosphatase; Alendronate; Animals; Animals, Newborn; Apoptosis; Biological Transport; Bone and | 2002 |
Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Clodronic Acid; Diphosphonates; Disease Models, | 2002 |
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
Topics: Alendronate; Animals; Apoptosis; Bone Density; Bone Resorption; Cell Survival; Dexamethasone; Glucoc | 2002 |
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Topics: Alendronate; Animals; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Gene Expre | 2002 |
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment.
Topics: Alendronate; alpha-Fetoproteins; Animals; Bone and Bones; Bone Remodeling; Bone Resorption; Calciton | 2002 |
Response of MBT-2 bladder carcinoma-induced osteolysis to various agents.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcitonin; Cyclosporine; Diphosphonates; Fem | 1992 |
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcium; Cells, Cultured; Chickens; Cyclic AM | 1991 |
Effect of alendronate (bisphosphonate) in animal models of hyperparathyroidism.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Calcium; Diphosphonates; Disease Models, Animal | 1991 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic | 1991 |
The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Bone Resorption; Diphosphonates; Female; Ovariect | 1991 |
Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
Topics: Alendronate; Animals; Bone Resorption; Cattle; Cell Survival; Diphosphonates; Etidronic Acid; In Vit | 1990 |
Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Carcinoma 256, Walker; Diphosphonates; Hypercalcemia | 1987 |